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Abstract
Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, an important
step in the control of blood pressure. The gene encoding for ACE is subject to an
insertion/deletion (I/D) polymorphism which is associated with different levels of the enzyme
in serum. This polymorphism accounts for 47% of the variability in serum ACE
concentrations between subjects but its relevance to tissue ACE is unknown. ACE inhibition
increases kinin level, for example bradykinin. Kinins have been proposed be involved in the
pathogenesis of cough due to ACE inhibitors, a common adverse effect in those prescribed
these drugs. A genetic link was proposed to explain the differing susceptibility of subjects to
develop cough. Those susceptible may differ in the cough reflexes initially or perhaps have
different degrees of tissue ACE activity. In this thesis I examined healthy subjects using
substrates and inhibitors of ACE to identify any possible differences in tissue ACE between
those of different ACE genotype. I also examined the natural history of ACE inhibitor cough
in particular changes in cough reflex and the possible roles of kinins in its aetiology. The
frequency of ACE genotype amongst those who developed cough was also examined.
a) The pressor response to angiotensin 1 was examined in 16 healthy subjects (DD, n=8; and
II, n=8). The R(d)25 was the rate of angiotensin I infusion which caused a 25 mmHg rise in
diastolic blood pressure. The geometric mean rate of infusion of angiotensin I required to
achieve the R(d)25 was 2.53pg/min in II subjects and 2.67pg/min in DD subjects (ratio of
doses (II:DD) = 0.95; 95% CI 0.44 to 2.02, p>0.05).
b) The hypotensive response and serum ACE responses to an ACE inhibitor drug were
examined in 27 healthy subjects grouped according to ACE genotype. Although changes after
enalapril paralleled those differences seen between the different genotypes before no
differences were seen between the groups when hypotensive responses were examined.
c) A prospective controlled study comparing subjects taking ACE inhibitors (n=21) with
those taking other anti-hypertensives (n= 12) examined the cough reflex changes that occur
during prolonged treatment using capsaicin challenge. A new cough developed in 8 subjects.
There were no differences in capsaicin sensitivity between groups at baseline. At one month a
significant increase in capsaicin potency from baseline was observed for patients with
enalapril cough (relative potency 4.7, 95% CI 1.2-18.5, p<0.025).
d) A prospective study examined different subjects (n=8) with cough as the ACE inhibitors
were discontinued and confirmed the change in cough sensitivity at day 28, this time to lie in
the opposite direction, (relative potency 0.2, 95% CI 0.1-0.7, p<0.05)
e) The dermal responses to bradykinin were examined in 105 healthy subjects (DD genotype,
n=30; ID genotype, n=51; and II genotype n=24). Using parallel line analysis the potency of
bradykinin in subjects of II genotype relative to those of DD genotype was 1.25, with a 95%
confidence interval of 0.83 to 1.88.
f) The cough response to bradykinin was examined in 27 healthy subjects (DD, n=9; ID, n=9;
and II, n=9). Bradykinin produced cough in 74% of subjects but there were no differences in
the cough responses between genotypes.
g) The distribution of ACE genotypes was examined in 31 patients with cough due to ACE
inhibitor. No increase in frequency of one genotvpe over another was identified. (DD, n=12;
ID, n=I3; II, n=6)
In conclusion the I/D polymorphism in the ACE gene could not predict responses to either
substrates of ACE or ACE inhibitor drugs in healthy subjects. The cough due to ACE
inhibitors leads to reversible changes in cough reflex sensitivity. Individuals who develop
cough do not seem to differ in their initial cough reflexes nor in their genotype in the I/D
polymorphism of the ACE gene.
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1.1 HISTORY OF THE RENIN-ANGIOTENSIN SYSTEM
It is almost 100 years since Tigerstedt and Bergman initiated research into the renin-
angiotensin system. In 1898 whilst trying to isolate the substance thought to cause uraemia
they identified a substance from rabbit renal cortex, named renin, which when injected caused
a rise in blood pressure (Tigerstedt 1898). These findings were not easily reproducible and
their importance not appreciated at the time. It was many years later before interest in renin
was rekindled. The focus of circulatory research at that time was to establish a cause for
hypertension, with particular emphasis on renal causes. Goldblatf s group proposed that
narrowing of the renal artery caused hypertension and demonstrated this by becoming one of
the first to develop a stable model for experimental hypertension (Goldblatt 1934).
Renin was active only when mixed with plasma suggesting that there was a co-factor within
plasma which facilitated vasoconstriction. Later isolated by Page and Helmer this co-factor
was named angiotonin (Page & Helmer 1940) and is now known as angiotensin. In 1939
Braun-Menendez et al purified a pressor substance from ischaemic kidneys which was active
without the presence of renin. He called this substance hypertensin and it was subsequently
renamed angiotensin (Braun-Menendez et al 1939).
During the 1950s there was intense competition to isolate the angiotensins. Skeggs showed
that two smaller molecular weight proteins named by him hypertensins 1 and 2 (later renamed
angiotensins I and II) were formed from angiotensinogen (Skeggs et al 1954). Angiotensin
converting enzyme (ACE), the enzyme producing angiotensin II, was characterised by Skeggs
as a chloride-dependant metallopeptidase (Skeggs et al 1956).
The development of specific inhibitors of the renin-angiotensin system in the 1970s led to
opportunities for therapeutic intervention and manipulation in this area. Peptides derived from
the venom of the snake Borhrops Jararaca were found to inhibit an enzyme involved in
bradykinin metabolism, kininase II (Ferreira 1965), now considered identical to ACE (Yang et
al 1970). The major stimulus for fractionation of this mixture was the demonstration that
these peptides also had a potent inhibitory action on the conversion of angiotensin I to II.
Among the peptides present in the venom a nonapeptide, teprotide, was the most thoroughly
studied (Antonaccio & Cushman 1981). In man teprotide was apparently safe and effective as
an antihypertensive drug but its peptide structure necessitated parenteral administration.
Teprotide raised the awareness of pharmacologists to the potential ofmanipulation of the
renin-angiotensin system as a method of blood pressure control. This heralded a systematic
search for oral inhibitors of angiotensin converting enzyme. The search for a simple non-
peptide that would interact with high affinity at the active site of ACE led to the development
of captopril by Cushman et al in 1977. Captopril resembles the carboxyl terminal dipeptide
residue of teprotide (Cushman et al 1977). The presence of a sulphydryl group contributed
greatly to its enzyme binding affinity. Enalapril was the next ACE inhibitor developed by
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Patchett et al in 1980 differing from captopril in that the zinc ligand by which it binds to the
active site is a carboxyl group. ACE inhibitors have now become established therapy for
hypertension and heart failure. Tolerated well by most who take them they are now in
widespread use. A troublesome cough developing during treatment is probably the most
common side-effect now seen, first recognised in 1985 by Sesoko.
In 1990 Rigat et al described a polymorphism of the ACE gene consisting of the presence or
absence of an insertion. This insertion/deletion (I/D) polymorphism accounted for 47% of the
variance of serum ACE activity when studied within healthy volunteers (Rigat 1990). Further
interest in the possible phenotypic relevance of this polymorphism and its role in the renin-
angiotensin system was provoked by the work of Cambien et al in 1992 who noted certain
genotypic relationships of this polymorphism with the risk of ischaemic heart disease.
J
1.1 AIMS OF THIS THESIS
The renin-angiotensin system is now recognised as one of the most important regulatory
systems in blood pressure homeostasis. This thesis aims to examine various aspects of the
renin-angiotensin system, in particular angiotensin converting enzyme (ACE) and its
inhibition; whether a genetic variation in the ACE gene might affect the response to substrates
ofACE; and the propensity ofACE inhibition to cause cough.
The specific aims are outlined below.
1. To determine whether phenotypic differences exist between individuals of different
genotype for the I/D ACE gene polymorphism with regard to substrates of ACE as
indicated by:
a) The pressor and neurohormonal responses to angiotensin I
b) The hypotensive responses to ACE inhibitor drugs
2. To study prospectively aspects of the cough caused by ACE inhibitor drugs and
relationship to the I/D ACE gene polymorphism, in particular:
a) The effect of treatment with ACE inhibitors on the cough reflex in hypertensive subjects
b) The natural history ofACE inhibitor cough when treatment is withdrawn.
c) The effects ofACE inhibitors on the dermal wheal responses to bradykinin.
d) The dermal wheal response to bradykinin and relationship to ACE genotype .
c) The cough response to bradykinin and relationship to ACE genotype.
c) The I/D allele frequency in those with ACE inhibitor cough.
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1.2 BIOCHEMISTRY OF THE RENIN-ANGIOTENSIN SYSTEM
The renin-angiotensin system (RAS) is composed of a series of peptides and enzymes which
together are involved in maintaining vascular tone. The combination of the pressor effects and
the effects on electrolytes and fluid balance exert a major influence on blood pressure control.
This system depends on a sequence of enzymatic reactions which result in peptide activation.
The initial step is the conversion of angiotensinogen to angiotensin I by renin. Thereafter
angiotensin I is converted to the active peptide angiotensin II by angiotensin converting
enzyme (ACE). Angiotensin II acts through a membrane bound receptor leading to a variety of
responses depending on the target tissue (Table 1.1). The main actions are vasoconstriction
and release of aldosterone.
Angiotensinogen is a large glycoprotein composed of approximately 400 amino acids with a
molecular weight of 47,000 to 66,000 (Eggena et al 1976). Most is synthesised in the liver
but other tissues such as the kidney and brain are capable of producing angiotensinogen.
Production is enhanced by oestrogens and glucocorticoids (Peach 1984).
Renin is a glycoprotein with a molecular weight of 35,000 to 42,000. This acid aspartyi
protease cleaves the leucine-10-valine-l 1 bond from the aspartic (amino) end of
angiotensinogen to release angiotensin I (Yukosawa et al 1980). It has high substrate
specificity with angiotensinogen its only known substrate (Peach 1977). This is considered
the rate-limiting step of the RAS and the rate of renin secretion ultimately determines the
activity of the renin-angiotensin system (Skeggs et al 1967). Renin is synthesised, stored and
secreted mainly within the juxtaglomerular cells of the kidney. Stimulants to renin release
include vascular stretch of the afferent arteriole, the electrolyte content within the distal tubule
(sensed by the macula densa), and the sympathetic nervous system. Most circulating renin is
composed of inactive renin which has a higher molecular weight than its active counterpart
but has identical enzymatic characteristics when activated. The conversion of renin into its
active form in-vivo remains undetermined.
Angiotensin I is a decapeptide pro-hormone released from angiotensinogen. Its cleavage,
with the subsequent release of angiotensin II, is catalysed by angiotensin-converting enzyme
(ACE) or kininase II and occurs mainly on vascular endothelium throughout the body but
probably chiefly in the lungs (Ng & Vane 1968).
Angiotensin I is unlikely to have any pharmacological activity, whereas its product,
angiotensin II, is a potent vasoconstrictor, and also stimulates the release of aldosterone with
consequent actions on sodium, potassium and water homeostasis.
Angiotensin converting enzyme (EC 3.4.15.1; ACE) or kininase II is a glycoprotein with a
molecular weight of 130,000 - 140,000. It cleaves the dipeptide histidyl-leucine from the
carboxyl terminal of the decapeptide angiotensin I and is classified as a dipeptidyl
carboxypeptidase (Kokubu & Takada 1987).
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Angiotensin II is the physiologically active octapeptide of the renin-angiotensin system. It
acts through specific membrane bound receptors which are coupled to second messenger
systems such as the phospholipase C-phosphotidyl inositol and the adenylate cyclase-cyclic
AMP system (Timmermans 1993). The development of antagonists to angiotensin receptors
has lead to identification of several subtypes of receptor with different actions. At present all
the effects discussed below are considered to be due to mediated through the ATj receptor,
with the role of the AT2 less clear (Timmermans 1993).
Angiotensin II produces an increase in blood pressure mainly through vasoconstriction having
a potency approximately 40 times greater than that of noradrenaline. When infused
intravenously it elevates arterial pressure within seconds (Reid 1985), as a direct consequence
of an increase in systemic vascular resistance. Contraction of vascular smooth muscle occurs
by two mechanisms: (i) direct action of angiotensin II on smooth muscle and (ii) stimulation of
the sympathetic nervous system. Angiotensin II may also cause increases in blood pressure via
a central effect as angiotensin II receptors have been located in the area posterior to the
medulla oblongata which lacks a blood-brain barrier (Ganong 1984).
Angiotensin II has a strong stimulatory effect on the adrenal glands causing the secretion of
aldosterone (Gann et al 1964) with subsequent effects of sodium retention and water
homeostasis. Within the kidney angiotensin II causes vasoconstriction of the efferent arteriole
and subsequent effects at the juxtaglomerular apparatus inhibit the secretion of renin. It may
also have a direct effect on the proximal tubule to promote sodium retention. Other
physiological effects of angiotensin II include a direct action on atrial and ventricular cardiac
muscle producing a pronounced plateau of the action potential and an increased force of
contraction, but no direct effect on heart rate.
Although most angiotensin II is produced by ACE alternative production of angiotensin II
occurs by non-ACE enzymatic pathways, notably human cardiac chymase (Urata 1993).
Angiotensin II is degraded by aminopeptidase-N which cleaves an amino acid to form
angiotensin III, a much less potent vasoconstrictor.
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Table 1.1 Actions of angiotensin II
1. Vasoconstriction (Gunther 1982)
2. Aldosterone secretion from adrenal zona glomerulosa (Douglas 1979)
3. Sympathetic activity noradrenaline release from renal sympathetic nerves
central enhancement (Sumners 1983)
peripheral facilitation (Zimmerman 1981)
4. Vagal inhibition (Ajayi 1985)
5. Cardiac stimulation (Holubarsch 1993)
6. Vasopressin release from posterior pituitary
7. Renal effects
Inhibition of renin release (negative feedback) (Menard 1991)
Vasoconstriction (efferent > afferent) (Myers 1975)
Increased tubular sodium absorption (Wald 1991)
Glomerular mesangial constriction (Brenner 1982)
8. Stimulation of proto-oncogene c-fos (Kawahara 1988)
9. Dipsogenic actions (Fitzsimmons 1969)
1.3 ANGIOTENSIN CONVERTING ENZYME (ACE)
Skeggs established that ACE is a chloride dependent metallopeptidase with dipeptidyl
carboxypeptidase activity (Skeggs et al 1956). ACE is primarily involved in two important
physiological reactions; i) the conversion of the inactive decapeptide angiotensin I to the
potent vasoconstrictor angiotensin II, and ii) the degradation of the bradykinin.
1.3.1 DIFFERENT FORMS OFACE
Three forms of ACE are found in man. Most angiotensin converting enzyme is bound to the
membrane of endothelial cells. However there is also a soluble form of the enzyme found in
plasma, and a smaller isoenzyme found in testicular tissue (Soubrier 1993).
Immunohistochemical techniques have demonstrated that ACE is present within the vascular
endothelium ofmost organs, located principally on the luminal surface and in the caveolae of
endothelial cells (Caldwell et al 1976). ACE is attached to the surface membrane at its
carboxyl terminus so that the active sites are directed extracellularlv (Figure 1.1). ACE is also
expressed on the membrane of renal epithelium, human placental microvilli, choroid plexus,
prostatic tissue and the monocyte-macrophage system (Vuk-Pavlovic et al 1989, Caldwell et
al 1976, Ng & Vane 1968). The membrane form of ACE is often referred to as tissue ACE
however this term is often used rather loosely. The most common usage of the term tissue
ACE refers to all activity of ACE within a certain organ or tissue preparation, for example
reference to cardiac ACE would mean the activity of the membrane bound form and plasma
ACE (Samani 1991, Morgan 1994). Some in-vitro research involves isolated preparations of
tissue and in this context tissue ACE refers to the membrane form only (Morgan 1994).
ACE was first discovered in horse serum (Skeggs et al 1956), and ever since, the measurement
ofACE has largely been of the serum or soluble form. Soluble ACE is believed to be derived
by enzymatic release from the membrane bound form by an enzyme known as secretase
(Oppong 1993). Studies of this form of ACE have shown that the soluble form lacks the
carboxyl terminus which is considered to be the membrane anchor (Soubrier 1993). At present
the relationship between the membrane bound form and the soluble serum ACE remains
uncertain.



















Figure 1.1 The different location and nomenclature of ACE 9
1.3.2 STRUCTUREAND ENZYMATIC PROPERTIES
The structure of human ACE has been established by a combination of biochemical and
cDNA sequencing (Soubrier et al 1988). The endothelial ACE molecule is composed of two
large domains with a high degree of internal homology between them, suggesting an origin by
gene duplication. Within each of these homologous domains are found short amino acid
sequences identical to those at the active sites of other metallopeptidases such as neutral
endopeptidase (Soubrier et al 1988). Thus each domain has in its structure a potentially active
site. Each active site contains one zinc atom. The two sites may differ in substrate specificity
(Soubrier 1993). A highly hydrophobic region close to the carboxyl-terminal end of the
molecule probably acts as the anchor to the plasma membrane (Sen et al 1991).
1.3.3 SUBSTRATES OFACE
It was the specific cleavage of a dipeptide residue from the COOH-terminal of angiotensin I
which first brought the attention of biochemists to ACE. We now know that a large variety of
peptides with different C-terminal amino acid sequences can act as a substrate to ACE (Table
1.2). The necessary requisites for an ACE substrate are: (i) an amino acid with a free
carboxylic acid function at the C-terminal end and (ii) an amino acid other than proline on the
penultimate position. Other endogenous peptides hydrolysed by ACE are enkephalins,
substance P and substance K (Theile et al 1985), neurotensin (Skidgel et al 1984), B-
lipotrophin, and luteinizing hormone releasing hormone (Skidgel & Erdos 1985).
Phylogenetic studies link ACE to the RAS as a secondary association (Lipke & Olson 1988).
Mammalian ACE degrades bradykinin more efficiently than it activates angiotensin I (Ryan
1983) indicating that bradykinin may be the primary substrate of ACE.









ACE is activated by the presence of chloride ions and inhibited by a variety of natural and
synthetic compounds. Chloride concentrations exert considerable influence on the catalytic
activity of ACE (Shapiro 1983) with differing concentrations being optimal for the two active
sites (Soubrier 1993).
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Binding data suggest ACE from different tissues may differ with respect to which of the two
sites is the most active, as the equilibrium dissociation constants appear uniform within an
organ but varied between organs (Jackson et al 1987). Differences are found in the binding
dissociation constants for ACE in different parts of the heart and lungs: Ka atria > Ka lungs >
Ka ventricles (Yamada et al 1991). These differences may be due to varying local chloride
concentrations between tissues (Soubrier 1993).
1.3.4 THEACE GENE
In man a single gene codes for both membrane-bound, soluble and testicular ACE (Figure 1.2,
Hubert et al 1991). Located on chromosome 17q23 (Rigat et al 1992) it is transcribed as a
4.3kb mRNA species in endothelial cells or 3kb transcript in testicular cells (Hubert et al
1991).
The structure of the human ACE gene was determined by using overlapping genomic clones,
which together contained the entire sequence of the ACE gene, isolated from a lamda-phage
human DNA library (Hubert et al 1991). The human ACE gene contains 26 exons interrupted
by 25 introns and spans approximately 2 lkb ofDNA. The theory that the ACE gene
originated as a result of gene duplication is confirmed by the presence of two homologous
clusters of eight exons (exons 4-11 and 17-24). These exons have similar sizes and codon
phases at the exon-intron boundaries. The ACE gene is unique in ha\ing two alternate
promoter regions which vary in activity according to cell type. The somatic promoter region is
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/. 3. 5 GENETIC CONTROL OFACE
In 1990 Rigat et al described a polymorphism of the ACE gene which is located within intron
16 of the ACE gene and consists of the presence or absence of an insertion which is 287 base-
pairs in length and codes for an alu repeat sequence. This insertion/deletion polymorphism
accounted for 47% of the variance of serum ACE activity when studied within healthy
volunteers(Rigat 1990). The possible phenotypic relevance of this polymorphism and its role
in the renin-angiotensin system is discussed later in this chapter and throughout the thesis.
1.3.6 ACE INHEALTHAND DISEASE
Serum ACE activity is relatively constant within healthy individuals but can vary considerably
between subjects, differing up to six times (Alhenc-Gelas 1991). The factors responsible for
this variability have until recently remained unknown. Within subjects no temporal variation
or circadian rhythm has been demonstrated in serum ACE activity (Lieberman 1975) and it
does not appear to be affected by orthostatic position, modest physical work, salt depletion, or
food intake (Dzau 1988, Jackson 1986).
Elevated activity of serum ACE is seen in a number of granulomatous conditions, with
sarcoidosis being the most well recognised (Lieberman et al 1979). Increased activities may
be used both as an aid to diagnosis and to follow disease progression. The increased ACE
activity may reflect stimulation of the monocyte macrophage system (Friedland et al 1977,
1978). The percentage of patients with sarcoidosis with elevated activities of serum ACE
varies in different studies from 60 - 95% (Studdy & Bird 1989, Lieberman et al 1979, Eldund
& Blaschke 1986). Silicosis, asbestosis (Gronhagen-Riska et al 1978), active tuberculosis
(Studdy & Bird 1989), Gauchers disease, leprosy (Lieberman & Beutler 1976) and
hypothyroidism (Smallridge 1985) are all associated with increased ACE activity. ACE
activity is raised during pregnancy and the puerperium (Dux 1984). ACE within human
monocytes is induced, in the presence of glucocorticooids in-vitro (Vuk-Pavlovic 1989).
Increased urinary ACE activity has been proposed as an index of renal tubular damage
(Baggio 1981) with a raised serum ACE activity correlating strongly with the presence of
severe retinopathy in diabetes mellitus (Lieberman 1980).
A decrease in serum ACE has been reported in vascular pathologies involving endothelial
damage or disruption such as deep vein thrombosis (Drouet et al 1988), and endothelial
dysfunction related to cancers, leukaemias, and transplants (Romer & Schmitz 1984).
Reduced activity is seen following acute and chronic lung injury (Bedrossian et al 1978).
Iatrogenic causes of reduced serum ACE activity include chemotherapy and radiotherapy
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(Sorensen et al 1984; Rubin et al 1984), and of course treatment with ACE inhibitors.
Treatment with ACE inhibitors has no effect on serum ACE concentrations as measured by
RIA (Alhenc-Gelas et al 1983). Serum ACE activity is not altered in hypertension or heart
failure (Dzau 1990).
1.4 WHAT IS THE TISSUE RENIN-ANGIOTENSIN SYSTEM?
Until recently it was considered that the RAS existed largely within the vascular space
composed of individual peptides produced from different tissues, each regulated by different
stimuli and under feedback control. The discovery that many tissues or organs are capable of
forming all the components of the RAS, and indeed are able to generate angiotensin II, has
lead to interest in a concept of a tissue RAS. The circulating or intravascular and tissue
systems share a common function in producing angiotensin II. However the tissue system is
self-contained and may not be influenced by the same factors as the intravascular RAS. The
tissues or organs which independently produce All that acts locally are the heart, blood
vessels, brain and kidney. Evidence for the existence of these local tissue RAS comes from the
detection of individual peptides and their mRNA in isolated tissue preparations (Admiraal
1990, Campbell 1987, Symonds 1970, Ganten 1971, Ryan 1976, Deschepper 1986, Dzau
1987). Several enzymes can cleave angiotensinogen, such as cathepsin D (Hackenthal et al
1978) and pepsin (de Fernandez et al 1965), and renin is not therefore essential when such
enzymes are present.
Pharmacological studies have shown that pharmacodynamic effects of ACE inhibitors are not
clearly related to serum ACE concentrations, suggesting that these drugs may be affecting the
membrane bound enzyme which may be the most important for maximal effect.
In the vascular tree ACE has been localised to the endothelium, vascular smooth muscle,
adventitia and perivascular structures (Johnston et al 1992b). Webb et al (1988) perfused a
human forearm with angiotensin I to demonstrate that ACE in the blood vessels was
functionally active. Even ACE is not essential for a functioning RAS since several enzymes
including tonin (Boucher 1977), cathepsin G (Tonnesen 1982), trypsin (Arakawa 1980) and
kallikrein (Maruta 1983) can cleave angiotensinogen to produce angiotensin II directly.
Thus the emerging concept is that the major site of angiotensin production is within the
peripheral tissues and that local angiotensin production may in fact exceed plasma production
(Campbell 1987, Lees 1990, Samani 1991). It has been suggested that plasma concentrations
of angiotensin actually represent a spill-over from the tissues and that the function of the
circulating RAS is not to deliver angiotensin II to target organs but to deliver renin or
angiotensinogen to the local RAS's (Campbell 1985).
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1.5 WHAT IS THE FUNCTION OF THE TISSUE RAS?
The concept of a tissue RAS means that concentrations of circulating renin and angiotensin
may not represent true activity of the system in either health or disease (Samani 1991).
Although there is a large body of evidence supporting the presence of a local tissue RAS the
actual function of such a system remains unknown. Angiotensin II generated by tissue RAS's
may feed back and affect nearby cells (paracrine function) or influence the same cell to which
the ACE is attached (autocrine function). The function of tissue RAS's and angiotensin II
production may thus vary according to the site of production. ACE and angiotensin II could be
involved in regulation of regional blood flow and may play a crucial role in the local tonic
control of vascular resistance, modulation of local sympathetic activity and stimulation of
hyperplasia and hypertrophy (Dzau 1988). Tissue responses to endothelial damage may also
involve ACE and a local RAS (Johnston et al 1992). There are links between angiotensin II
and cell growth suggesting an association between local angiotensin production and tissue
hypertrophy. In Goldblatt experimental one kidney one-clip hypertension in the rat, serum
ACE does not increase but ACE within the hypertrophied mesenteric vessels and enlarged left
ventricle are significantly increased (Johnston 1991). Also, in a rat model of experimental left
ventricular hypertrophy, mRNA for ACE is increased within the myocardium (Schunkert et al
1990; Nagano et al 1991).
1.5.1 INHIBITION OF TISSUE ACE
The hypothesis that inhibition of tissue ACE (membrane-bound ACE) rather than serum ACE
explains the clinical effects of ACE inhibitors stems from a discrepancy in time-course
between serum ACE inhibition and haemodynamic changes. Inhibition of serum ACE
correlates with simultaneous plasma drug concentration (Ajavi et al 1987). However the
maximum blood pressure fall lags behind the peak plasma drug concentration (Wenting 1987).
This lag phase may be due to equilibration between serum and tissue sites, with subsequent
delayed inhibition of tissue RAS. Some single dose studies suggest a close relationship
between fall in blood pressure and serum ACE inhibition (Jackson 1984) but others find no
relationship (McFadyen 1993). Pharmacokinetic studies in rats show blood pressure
decreases correlating better with tissue ACE than serum ACE (Unger et al 1994). During long
term ACE inhibitor therapy, when steady state equilibrium has been reached, hyper-
reninaemia develops and angiotensin II is found despite continued hypotension. (Mooser 1990,
McFadyen 1991).
The time course of tissue ACE inhibition appears to vary from one organ to another
(Johnston 1988, 1989) but these findings are difficult to interpret and could be the product of
tissue bioavailability rather than true differences in enzyme affinity. Tissue differences are
more likely to be due to differences in penetration of the tissue, for example, if the lipid
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concentration of the local ACE environment is high then tissue penetration may be delayed.
The distribution of a drug between serum and tissue is likely to be a dynamic equilibrium and
depending on quantitative availability of binding sites and the properties of the individual ACE
inhibitor or tissue site.
Thus tissue ACE could be more important than inhibition of circulating ACE when discussing
the clinical effects of ACE inhibition. Problems arise on further investigation of this concept
because although serum ACE concentrations are relatively easy to measure accurate
measurement of tissue ACE in man is difficult.
1.6 THE RENIN-ANGIOTENSIN AND BRADYKININ-KALLIKREIN SYSTEMS
Bradykinin is a nonapeptide component of the kallikrein-kinin cascade, active in mediating
inflammatory responses. The bradykinin-kallikrein system and the RAS are linked by
angiotensin converting enzyme which is considered identical to kininase II (Yang et al 1970).
ACE is responsible for the majority of the degradation of bradykinin within the lung and a
proportion of bradykinin degradation within the plasma (Erdos 1975, Ryan 1968).
Kallikrein circulates in an inactive form until activated by many noxious stimuli. It cleaves a
kinin called kallidin which is converted to bradykinin by tissue enzymes. Bradykinin has
actions throughout the body including relaxation of vascular smooth muscle, plasma
exudation and mediation of inflammatory pain. Bradykinin also stimulates histamine release.
When injected intradermally bradykinin causes a dose-dependent wheal and flare response
(Fuller 1987). The effects of bradykinin on the airways have been related to its ability to cause
release of neuropeptides from sensory nerves such as C-fibres. Subsequent activation of
cholinergic pathways can lead to bronchoconstriction in laboratory animals. In small studies
bradykinin had a bronchoconstrictor response in those with asthma but not in healthy
individuals (Simonsson 1973, Fuller 1987). Cough, unrelated to any change in airways
calibre, was observed to varying extent in these and other studies (Dixon 1987, Choudrv
1989, Ichinose 1992). However these studies were not designed to look for cough specifically
and gave little information on its nature or severity.
1.7 COULD THE ACE GENOTYPE BE OF IMPORTANCE9
Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, an important
step in the control of blood pressure and sodium balance. As discussed above the gene
encoding for ACE is subject to an insertion/deletion (I/D) polymorphism associated with
different concentrations of the enz}me in serum (Rigat 1990). Subjects homozygous for the
deletion allele (DD) have serum ACE concentrations 48% higher than those homozygous for
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the insertion allele (II), while heterozygotes (ID), have intermediate concentrations (Rigat
1990). This polymorphism accounts for 47% of the variability in serum ACE concentrations
between subjects.
The phenotypic significance of the ACE gene polymorphism had been studied little at the
outset ofmy work. As discussed above ACE is distributed widely throughout the tissues,
largely bound to cell surfaces, especially on the vascular endothelium (Caldwell 1976).
Knowledge about the role of the I/D polymorphism in determining ACE bound to cells and
thus tissue ACE was much less certain with only a single study examining this area when my
research began (Costerousee 1993). In this study the I/D polymorphism was shown to
influence the distribution of ACE concentrations in human T lymphocytes (Costerousse 1993)
but the relationship was not as strong as with serum ACE.
To my knowledge its effect on the expression of ACE at the vascular endothelium had not
been examined. The I/D polymorphism is confined to humans and limits potential research
pathways thus models of tissue ACE were developed from previous work.
Further impetus to examine the ACE gene polymorphism came following several reports of a
possible link between it and vascular disease. A case-control study from Europe suggested
that the presence of the deletion allele may be a risk factor for myocardial infarction (Cambien
1992). Thus emerged a genetic marker which might help explain why individuals free of
recognised risk factors develop ischaemic heart disease. Further case-control studies suggested
that the deletion allele was a risk factor in those with ischaemic and dilated cardiomyopathy
(Raynolds 1993), and for the development of left ventricular hypertrophy (Schunkert 1994).
The mechanism by which the D allele may exert these detrimental effects is unknown, but
could be through an enhanced rate of production of angiotensin II resulting in increased
pressor and trophic cardiovascular responses. This enhanced rate of production might occur
within the serum or in localised tissue systems such as the heart. Alternatively of course it
could be acting as a marker in linkage disequilibrium with another as yet unknown gene.
Identifying those at risk might in the future identify people who may benefit from treatment. If
the ACE genotype could be linked to phenotypic differences in the RAA system then perhaps
susceptible individuals might be targeted with drugs such as ACE inhibitors (Swales 1993)
The responses to ACE inhibitors probably relate to inhibition of both serum and tissue ACE.
The evidence as to the relationship between the initial serum ACE and the hypotensive
response is conflicting with some finding a relationship (Johnston 1983, Jackson 1984) and
others not (McGregor 1981, McFadyen 1993).
Through its strong association with serum ACE activity the ACE genotype may predict not
only antihypertensive effects but possibly also adverse effects such as hypotension in heart
failure. This might allow targeted treatment to those who would respond optimally and also
recognition of those who might develop severe hypotension. One might argue that we can
17
already increase the chances of response to ACE inhibitor simply by adding a diuretic to
activate the RAS and that it is not necessary to know who might respond most. However
knowledge of genotype might also be helpful in determining those who may become
susceptible to other adverse effects such as cough. Indeed it has been suggested that the reason
why cough should only affect 20% of those given ACE inhibitors may be linked to ACE
genotype (Yeo 1991). Those individuals with lower ACE concentrations (II subjects) may
develop increased concentrations of bradykinin and substance P with alteration in cough
threshold.
Thus the ACE genotype could give further insight into the complex nature of the renin-
angiotensin system in health and disease and possible predict both beneficial and adverse
responses to ACE inhibitors.
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1.8 ANGIOTENSIN CONVERTING ENZYME INHIBITORS
1.8.1 ACE INHIBITIONAND THE RENIN-ANGIOTENSIN SYSTEM
It is generally considered that the effects ofACE inhibitors are largely due to inhibition of by
inhibition of serum and membrane bound ACE resulting in a decrease in ACE activity and fall
in angiotensin II (Edwards & Padfield 1985). ACE inhibition blocks the vasoconstriction
induced by infusion of angiotensin I (Given 1984). Following administration of an ACE
inhibitor there are reductions in angiotensin II and aldosterone (Atlas 1984, Lijnen 1982, De
Leuw 1983)and increases in angiotensin I and renin concentrations. Angiotensin II
concentrations drop within 30 mins to 4 hours depending on the ACE inhibitor (Atlas et al
1984). ACE inhibition also results in inhibition of bradykinin metabolism with consequent
vasodilatation. Activation of the arachidonic acid cascade by ACE inhibitors results in the
production of vasodilatorv prostaglandins (Swartz & Williams 1982). Both these additional
effects are additive to the vasodilatation produced by reduction in angiotensin II levels.
The resulting arterial vasodilatation leads to a reduction in systemic vascular resistance which
is more pronounced in the hepatorenal vascular beds than those of the brain or skeletal muscle
(Ibsen et al 1984). A single dose of ACE inhibitor can reduce the systemic vascular resistance
by up to 15% and long term therapy reduces it a further 15% to 30% (Dunn 1984). The
majority of this effect is seen in resistance vessels, arterioles, but larger conduit vessels are
thought to dilate also.
The decrease in systemic vascular resistance is the predominant mechanism by which ACE
inhibitors reduce blood pressure. In normotensive human subjects a single dose of an ACE
inhibitor can reduce the blood pressure by 5 to 20 mm Hg (Brunner 1981, MacGregor 1981).
If the RAS is activated, for example in sodium depletion then the hypotensive response is
accentuated (MacGregor 1992, Jackson 1984, Swartz 1982, Atkinson 1979, Man in't Veld
1980). Whether the hypotensive effect of ACE inhibitors is initially proportional to the
inhibition of the enzyme remains uncertain with Johnston et al (1983) showing a close relation
between reduction in serum ACE activity and the fall in blood pressure in hypertensive
subjects after a single 10 mg dose of enalapril and other authors showing no relationship with
serum ACE activity reduction achieved. Unlike other arterial vasodilators used in
hypertension administration of an ACE inhibitor does not cause a reflex tachycardia
(Weinberger 1982) possibly due to alteration in the baroreceptor reflexes caused by reduced
All (Guidicelli 1985).
Difficulty in measuring plasma concentrations of the components of the RAS has led to
variable results when trying to predict the effects to ACE inhibitors. The determination of
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plasma renin activity by radioimmunoassay has been used most commonly (Sealey & Laragh
1977) correlating well with angiotensin II-mediated vasoconstriction.The hypotensive effects
persist longer than suppression of serum ACE concentrations (Gavras et al 1981) suggesting
that ACE inhibitors may mediate their effects via a tissue RAS as discussed earlier.
1.8.2 ACE INHIBITIONAND THE BRADYKININ-KALLIKREIN SYSTEM
As discussed above, the enzyme associated with degradation of bradykinin, kininase II, is
identical to ACE, ACE inhibition would therefore be expected to increase concentrations of
bradykinin. This is not easy to demonstrate as the bioassay of kinins is difficult and not
particularly accurate or reproducible (van Leeuwen 1983). Furthermore kinins are generally
considered local mediators and measuring plasma kinins may not necessarily reflect changes
at local sites. They are also inactivated by many different enzymes apart from ACE and these
may easily counter the effects ofACE inhibition. Reports of the responses of circulating
bradykinin levels to ACE inhibition are variable with some groups reporting increases (Crantz
1980, Swartz 1982) and others failing to show any change (Given 1984, Odya 1983). ACE
inhibition enhances the contractile effects of bradykinin on guinea-pig ileum and the
vasodilation of guinea pig coronary artery (Zusman 1984, Yiang 1985). In man, Lindgren
(1988) demonstrated a dose-response relationship for dermal wheal production using
intradermal bradykinin during ACE inhibition. Wheal thickness increased after enalapril
treatment in healthy volunteers (Femer et al 1987, Li Kam Wa 1993) and hypertensive
patients (Ferner 1989). Thus the wheal response to intradermal bradykinin may be used as an
indirect measure of membrane ACE activity. Benjamin et al (1989) suggested that the effects
of enalaprilat infusion on vasodilatation are mediated through both angiotensin II reduction
and bradykinin potentiation. Indeed administration of competitive antagonists of bradykinin
can partially reverse hypotensive effects of ACE inhibition (Seino et al 1989). Bradykinin has
been found in increased serum concentrations in those with cough on ACE inhibitors
compared with a control group, and it may be a mechanism for this side effect (Puolijoki
1992). As discussed above however bradykinin concentrations are difficult to measure and
this work has not been reproduced.
1.8.3 ACE INHIBITORS INHYPERTENSION
ACE inhibitors are effective antihypertensive agents causing falls in blood pressure similar to
those of other classes (Pool 1989, TOHMS 1991). Hypotensive effects ofACE inhibitors are
additive to those of the thiazide diuretics (Wing 1987) and dihydropyridine calcium
antagonists (Salvetti 1987). Initial studies examining side effects compared them to outdated
agents such as methyl-dopa and it was not surprising that they resulted in a better "quality of
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life" (Croog 1986). A number of studies since have failed to show important positive benefits
of ACE inhibitors on quality of life, and they have not proved superior to beta-blockers such
as atenolol (Steiner 1990, Fletcher 1990, Herick 1989, THOMS 1994, Jones 1995). Overall
evidence suggests that ACE inhibitors are as well tolerated as the other main classes of
antihypertensive drugs and have similar effects on quality of life (TOHMS 1991, 1994,
Maclean 1990).
The side effects ofACE inhibition are described in more detail below. In general, ACE
inhibitors are relatively free of contraindications, and can be used safely in patients with
coexisting disease states such as diabetes, chronic obstructive airway disease, and heart
failure. ACE inhibitors have a particularly invaluable role when hypertension is complicated
by heart failure due to the both the beneficial effects found in the treatment of heart failure
with ACE inhibitors and the relatively negative inotropic effects of other agents with the
exception of diuretics. They may also have some benefit on renal function in insulin-
dependent diabetic patients where proteinuria and the decline in renal function observed in
diabetic nephropathy is reduced (Lewis 1993).
In summary, ACE inhibitors are comparable to the thiazide diuretics and beta-blockers as
regards their efficacy in lowering blood pressure, simplicity to prescribe, and tolerability.
Their efficacy in preventing cardiovascular and cerebrovasular end-points in hypertensive
subjects remains to be established with respect to older agents but studies are underway and
recent favourable results in those with heart failure support the view that they are likely to
prove beneficial.
1.8.4 TREA TMENT OFHEART FAILURE WITHACE INHIBITORS
The use of ACE inhibitors for the treatment of heart failure soon followed their use in
hypertension and the combination of a diuretic and ACE inhibitor is now standard treatment
for chronic heart failure. Several large randomised controlled studies showed that ACE
inhibitors reduced mortality and morbidity in heart failure of varying degrees of severity. The
CONSENSUS trial study group (1987) showed that ACE inhibitors significantly increased
survival in patients with severe heart failure when compared to placebo. VeHFT II evaluated
ACE inhibitor compared to the combination of hydralazine and isosorbide dinitrate in those
with moderate congestive heart failure (Cohn 1991). Enalapril significantly improved survival
at two years compared to the combined treatment which was previously the treatment of
choice in this condition. Recently, the results of several large mortality studies investigating
the value of ACE inhibitor treatment in terms of heart failure prevention and improved
survival have been published (The SOLVD investigators 1991; 1992; Pfeffer 1992). They
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demonstrated that the use ofACE inhibitors as therapy in left ventricular dysfunction in
patients reduces not only mortality, but also the progression of heart failure, the number of
hospitalisations and the rate of cardiovascular events. Following myocardial infarction ACE
inhibitors reduce mortality when patients have left ventricular dysfunction which is either
clinically apparent (AIRE study 1993) or detected by measurement of left ventricular ejection
fraction (SAVE study 1992).
1.8.5 SIDE EFFECTS OFACE INHIBITORS
Considerable experience of long-term use of ACE inhibitors has accrued, and it seems clear
that they are generally safe drugs. Neutropenia, proteinuria, skin rashes, loss of taste, and
angio-oedema were all documented with the initial use of captopril. These effects, with the
exception of angio-oedema, seemed to be associated with the high doses initially recommended
and are now rare. With the doses currently prescribed the main adverse effects seen are cough,
renal impairment, hypotension and angio-oedema. Persistent dry cough is the most frequent
side effect of ACE inhibitor therapy and is discussed below.
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Table 1.3 Summary of the most common subjective side effects of ACE inhibitors.
Subjective side-effects-approximate incidence in controlled studies (Yeo 1990, THOMS 1994)
dry cough










fatigue 1 - 3%
1 - 3%
1 - 4%
Some effects such as taste disturbance, and rash are related particularily to the sulphydryl
group in certain ACE inhibitors and therefore are less commonly seen when using an ACE
inhibitor containing a different zinc ligand. The more important potential side effects are
discussed in brief below.
Angioedema is a rare but potentially serious side-effect with an incidence estimated at 0.05-
0.1% (Hedner et al 1992; Slater et al 1988) and occurs following the first dose or within 48
hours of initiating therapy (Femer et al 1987). Angioedema commonly affects the face, lips,
tongue, hands, feet and scrotum. Usually it is mild and subsides on withdrawal ofACE
inhibitor treatment. In a few patients it may involve the pharynx or larynx with serious
consequences. Treatment is usually by giving corticosteroids, adrenaline or even
tracheostomy. The cause is unknown but may be due to potentiation of the subcutaneous
effects of bradykinin in those susceptible.
Hypotension is more of a problem in patients with heart failure than hypertension. In patients
treated on high doses of diuretics, or with bilateral renovascular disease, who may have high
plasma renin activity before treatment, falls in systolic blood pressure of up to 50 mmHg may
occur, this may cause syncope or even very rarely stroke or myocardial infarction (Webster
1987). Venodilation is the probable cause of the hypotension and the absence of a
compensatory tachycardia suggests a parasympathetic action similar to vasovagal syncope
(Capewell 1991). Simple ways to reduce the occurrence of this side effect include stopping
diuretic therapy for a 1-2 days on initiation ofACE inhibitor therapy. If a patient is
considered at high risk admission to hospital is recommended. There has been a suggestion of
differences between ACE inhibitors in their potential to cause first dose hypotension
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(McFadyen et al 1993) but this probably relates to half-life. Perindopril has a relatively long
half-life and causes significantly less hypotension than captopril following a single dose
(McFadyen et al 1993).
Renalfailure due to ACE inhibitors may be severe and progressive in patients with advanced
renovascular disease, particularly those with a tight stenosis of the artery supplying a solitary
kidney, unilateral renal artery thrombosis and contralateral renal artery stenosis, or bilateral
renal artery stenosis (Verbeelen 1984). In these cases glomerular filtration is maintained by
angiotensin II-induced constriction of the efferent arterioles. ACE inhibition abolishes this
constriction, and dilates the efferent arterioles causing filtration pressure to fall to such low
levels that renal failure develops. The effect of ACE inhibitors on advanced renovascular
disease is of considerable practical importance. Patients "at risk" are relatively common
among those with resistant hypertension, the elderly, and those with peripheral vascular
disease. Renovascular disease even of such a severe degree can often be clinically "silent",
therefore, it is essential when prescribing an ACE inhibitor to measure serum creatinine before
starting treatment and remeasure it during treatment in order to observe for any decline in
renal function.
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1.9 ACE INHIBITOR-INDUCED COUGH
1.9.1 PHYSIOLOGY OFCOUGH REFLEX
The cough reflex protects the respiratory tract from a variety of irritants and clears associated
secretions. Its control is by a complex interplay of receptors, neuronal pathways and central
nervous system modulation.
A normal cough response begins with an initial deep inspiration and closure of the glottis,
followed by contraction of the expiratory muscles causing a rapid increase in intra-thoracic
pressure. The glottis then opens as muscular contraction continues to increase the pressure,
forcing air out at high velocities. There are many variations on this basic pattern, with cough
occurring as a single episode or in paroxysms with each cough occurring at lower lung
volumes (Langlands 1967).
Many different mechanical and chemical stimuli can induce cough. The larynx and carina are
particularly sensitive to cough (Fillenz & Widdicombe 1970, Sant'Ambrogio 1987) but cough
can be produced by stimulation at several other sites in the upper airways. Central nervous
control modulates the basic cough pattern producing a complex and often varied response to
different stimuli. A discrete cough centre has not been identified in man but integration and
modification of sensory data probably occur in an area distinct to the respiratory centre. In the
cat specific electrical stimulation of the midbrain can cause pure cough with -virtually no effect
on respiration or blood pressure (Kase 1970). That cough can be voluntarily generated or
suppressed suggests higher centres have a modifying role.
1.9.2 COUGH RECEPTORSAND AFFERENT FIBRES
The airways and lung are derived embryologicallv from the forepouch of the gut, and share
the same nerve supply - the vagus nerve. Stimulation of the alveoli, external auditory meatus,
pharynx and diaphragm, can initiate the cough reflex as a result of their common
embryological origin and shared nerve supply (Todisco 1982). Afferent impulses along the
vagus nerve travel in either myelinated or non-myelinated fibres. Myelinatedfibres can be
subdivided according to electrophysiological properties of the receptor stimulated into
rapidly adapting (RAR's) and slowly adapting receptors (SAR 's). Non-myelinated fibres are
classified as either bronchial or pulmonary C-fibres. RAR's are found predominantly in the
larynx, trachea and carina and SARs within the bronchial smooth muscle. Pulmonary C-
fibres are located within the alveoli. Both stimulation ofRARs and C-fibres may result in
cough in humans (Barnes 1986).
Rapidly adapting receptors (RARs) are located superficially within the airway mucosa, either
below or between the epithelial cells (Davis et al 1982). They are particularly numerous at
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branch points of the tracheo-bronchial tree. In general they respond to light mechanical
stimulation and weak chemical stimulation, for example, citric acid (Banner 1986, Pounsford
1985). RARs adapt quickly and fire irregularly (Karlsson 1988) and are stimulated by many-
tussive stimuli. Partial block of vagal conduction limited to myelinated fibres inhibits the
cough reflex (Widdicombe 1954, 1980, Karczeqski & Widdicombe 1969). RARs may play an
important role in the generation of cough, particularly cough arising from the upper airway.
C-fibres are found in the airway epithelium close to the basement membrane and nearer to the
airway lumen (Barnes 1986). They outnumber the myelinated fibres by estimates from 3-11:1
(Sant'Ambrogio 1982, Jammes et al 1983) in the cat vagus. Substance P and other sensory
neuropeptides are released as part of a local axon reflex (Barnes 1986). Tussive chemical
agents such as capsaicin (Coleridge et al 1964; Winning et al 1986), bradykinin (Kaufman et
al 1980), histamine, PGE2 (Choudry et al 1989), PGF2a (Nichol et al 1990), and sulphur
dioxide (Coleridge & Coleridge 1984) all stimulate these nerves.
J.9.3 COUGH INDUCED BYACE INHIBITORS
First described ten years ago, persistent dry cough is now recognised as the most common
subjective side-effect during long-term treatment with ACE inhibitors (Fletcher 1994, DTB
1994). Many studies have confirmed its high incidence and that it is the most frequent reason
for stopping treatment (Lernhardt & Ziegler 1988, Israeli et al 1992, Yeo et al 1991).
Important gaps remain in the knowledge of the natural history of the cough, its pathogenesis,
and factors which predispose subjects to the cough.
1.9.4 HOWCOMMON ISACE-INHIBITOR COUGH?
Different studies have shown a wide range of estimates for frequency of cough with ACE
inhibitor ranging from about 3% in postmarketing surveillance studies to 22% by direct
enquiry in controlled trials. That cough was not immediately considered as a potential side
effect of drugs was apparent from post-marketing surveillance studies which provided
estimates of 2-3% when ACE inhibitors were initially studied (Coulter and Edwards 1987,
Inman 1988). Relying heavily on spontaneous reporting of symptoms will underestimate the
incidence of cough as demonstrated by these studies. As cough is such a common symptom
that it was clearly not considered relevant by patients. Likewise their medical attendants did
not predict this unique adverse effect would occur given the pharmacological properties of this
class. When they began to be used in clinical practice case reports of patients taking ACE
inhibitors who had developed cough provoked further study (Sesoko 1985). Uncontrolled
studies in hospital clinics (Gibson 1989, Strocchi 1989) suggested an incidence of cough
between 6 - 15 %. Controlled studies using validated methods of ascertainment show that the
true incidence of ACE inhibitor cough is about 15-20 % (Fletcher et al 1990, Yeo et al 1991a,
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Yeo ct al 1991b). The incidence of cough as measured by spontaneous reporting was 16% in a
study which was uncontrolled but analysed by a life-table method. This was in addition to the
6% of patients who had already stopped treatment because of cough (Yeo & Ramsay 1990).
In a similar study the prevalence of cough was 10% with captopril or enalapril treatment,
when compared to hydrochlorothiazide (Sebastian et al 1991).
A later study showed that over two thirds of patients with cough detected by questionnaire,
but not volunteering it when seen in clinic described their cough as moderate or severe (Yeo et
al 1991a). In controlled studies direct enquiry using methods such as verbal questioning, self-
administered questionnaires or visual analogue scales were used. Even here the assessment of
symptom severity may be difficult because such trials are usually of short duration. Patients
will often continue taking treatment for a pre-determined period, enduring symptoms which
would otherwise make them stop the drug. Methods of direct enquiry will overestimate the
incidence of cough in uncontrolled studies because of the high prevalence of chronic cough
related to smoking and chronic respiratory disease (Barbee et al 1991), and are therefore
reliable only in controlled comparative trials, even then only when corrected for baseline
responses. Visual analogue scales (Yeo et al 1991b) are also of value in the setting of
controlled trials, but are probably inferior to the use of simple questions because of variability
within subjects in scoring.
When assessed by visual analogue scale the prevalence of cough with enalapril, compared to
nifedipine, was 22% after six months in a double-blind controlled trial (Yeo et al 1991). The
most reliable estimate of the incidence of cough comes from random prospective controlled
trials using questionnaires (Fletcher et al 1990), and is about 20%. These estimates are all in
general agreement with the figure of 15% derived by Just (1989) from an overview of
published data.
1.9.5 WHO GETSACE INHIBITOR COUGH?
Why only 20% of the patients treated with ACE inhibitors develop dry cough is unknown. The
cough is probably a consequence of the non-specific pharmacological action of ACE
inhibitors, related to their inhibition of the kininase action ofACE rather than interruption of
the conversion of angiotensin I to angiotensin II. Kininase inhibition may cause accumulation
or imbalance of putative mediators of cough such as bradykinin, substance-P and
prostaglandins at the cough receptors served by C-fibres (Choudry et al 1989b). Changes in
the cough reflex have been shown with individuals developing a marked increase in sensitivity
during ACE inhibitor treatment (McEwan et al 1989). Subjects who develop ACE inhibitor
cough seem to have a normal cough reflex initially, but develop a marked shift to the left of
their cough responses to capsaicin (McEwan et al 1989) indicating an effect on C-fibres
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(Berkin & Ball 1988). The limited evidence available suggests that ACE inhibitors affect the
cough reflex only in these patients (McEwan et al 1989, Morice et al 1987), and that there is
no change in the remainder of those treated. Sex and smoking habit are the only factors
identified at present related to development of ACE inhibitor cough. Many studies have
confirmed a preponderance ofwomen among those who develop cough, with a female:male
ratio of about 2:1 (Yeo et al 1991a; Yeo et al 1991b; Yeo & Ramsay 1990; Just 1989; Os et
al 1992). Even these may not be true risk factors as other reasons may lead to over or under
reporting of this side effect in these groups. Women might report cough more readily (Os
1992), and have a lower threshold to tartaric acid (Fujimura 1990). A large double-blind
placebo-controlled study with lisinopril (Os et al 1992) confirmed previous suggestions (Yeo
et al 1991) that non-smokers are more likely than smokers to develop cough as a side-effect.
The incidence of cough was 16% in non-smokers compared to 7% in smokers (Os et al 1992).
In clinical practice this difference may be exaggerated as smokers and their attendants are
more likely to ascribe the cough to the effects of tobacco rather than a drug.
There does not seem to be any relationship between ACE inhibitor cough and pre-existing
airways obstruction, age, body weight, renal function, duration of treatment, or use of other
antihypertensive drugs (Yeo et al 1991a). There is no convincing evidence that different ACE
inhibitors differ in their propensity to cause cough (Ravid 1994).
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1.9.6 CLINICAL FEA TURES
Most, perhaps 85%, of those who develop cough do so within the first month ranging from 2
days to several months (Fletcher 1990, Lacourciere 1994). Specific features of the cough and
associated symptoms are largely derived from research that examined multiple symptoms in
detail by questionnaire in a non-random but controlled comparison with nifedipine (Yeo et al
1991a). It was shown that cough with ACE inhibitors is characteristically dry or non¬
productive, and in this respect differs significantly from the cough related to respiratory
disease, which is usually productive of sputum. It is persistent, repetitive, occurs in bouts,
and is prominent at night (Webb 1986). Other symptoms associated with cough are voice
change (hoarseness or huskiness) in 14% and throat discomfort in 10% of patients. Any one of
these "laryngeal" symptoms (cough, voice change or throat discomfort) is present in 24% of
patients after two years of treatment (Yeo et al 1991a).
In about 25% of patients with cough it is severe enough to necessitate withdrawal of the ACE
inhibitor. (Yeo et al 199 la, Yeo et al 199 lb). If treatment is continued most consider their
cough to be moderate or severe, and in the majority it disturbs sleep and is a nuisance to
others (Yeo et al 1991a). It may remit spontaneously if treatment is continued, but this is
probably uncommon (Reisin and Shneeweiss 1992) and may suggest an alternative aetiology
such as post viral cough. In some patients the bouts of coughing cause vomiting (Yeo et al
1991a). If it is considered important that an ACE inhibitor is given then a re-challenge with
either the same drug or an alternative ACE inhibitor might be w orth attempting. During the
entry phases of a study examining the effects of an All antagonist on cough, patients with a
history of ACE inhibitor cough were re-challenged with ACE inhibitor. It is of note that 28%
of these subjects failed to develop cough again after eight weeks treatment (Lacourciere
1994).
1.9.7 DIAGNOSIS AND TREATMENT
When a cough with typical features develops in a patient taking an ACE inhibitor it should be
assumed that the drug is the cause. The cough of asthma, oesophageal reflux, bronchial
carcinoma or post-nasal drip may have similar features (Puoloki 1989). However a chest X-
rav and spirometry are probably the only investigations required initially. If diagnostic doubt
remains it should be resolved by withdrawing the ACE inhibitor.
Several treatments have been suggested for ACE inhibitor cough. There is some relation
between the dose of ACE inhibitor and development of cough as demonstrated in patients with
enalapril-induced cough. In this study halving or doubling of the dose of enalapril under
controlled conditions altered the frequency and severity of coughing. Curiously there was no
effect on the cough reflex as assessed by responses to inhaled capsaicin however this may
have reflected a small sample size (Yeo et al 1995).
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When the ACE inhibitor is stopped the cough usually disappears within 2-10 days, but in
some patients, perhaps those who have has the cough for a long time, it may take several
weeks for the cough to disappear (Reisin and Shneeweiss 1992). A case report of resolution
with sulindac led to further study of non-steroidal anti-inflammatory drugs (Gilchrist et al
1989), but claims that this group of drugs or others such as theophylline (Pomari et al 1989)
abolish or improve ACE inhibitor cough have not been substantiated, and until recently no
treatment was proved effective. Classes of drug which block the renin-angiotensin system
more selectively, such as angiotensin antagonists or renin-inhibitors, may prove free of this
side-effect. This hypothesis is supported by a recent study with losartan, a specific antagonist
of angiotensin II at AT j receptors. When examined in a group of subjects who coughed with
ACE inhibitors on 2 separate challenges the incidence of cough was indeed significantly less
than ACE inhibitors (Lacourciere 1994) however about 29% of subjects given losartan still
did develop cough again for reasons that are not immediately apparent. The incidence was also
similar in the group randomised to bendrofluazide (34%) a drug not recognised as causing
cough.
When faced with a patient with cough due to ACE inhibitors there are several newer treatment
options which have been recently examined. The first option would be to change from an ACE
inhibitor to an angiotensin II antagonist such as losartan. If it is considered that the ACE
inhibitor has to be continued then the use of inhaled sodium cromoglycate (Hargreaves 1995)
has been demonstrated to have some effect. The efficacy of this drug also lends further
support to the involvement of kinins. Clinical experience suggests that once the cough has
developed patients are often reluctant to continue with treatment particularly in those with
hypertension. Other groups have persuaded their patients to continue for longer periods and
identified that the cough may resolve or diminish in intensity in up to 25% of patients.
Whether this is affected by adaptation of the cough response or the fact that the cough was
related to other causes for example respiratory viruses is unknown (Reisin 1992, Ravid 1994).
In summary, Dry cough leads to withdrawal ofACE inhibitor treatment in about 5% of
patients and is a persistent nuisance in a further 15%. It is often accompanied by voice change
and throat discomfort, and affects women and non-smokers particularly. There is no effective
treatment. It is related to inhibition of kininases rather than the action ofACE inhibitors on
angiotensin conversion.
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1.10 AIMS OF THIS THESIS:
1. To determine whether phenotypic differences exist between individuals of different
genotype for the I/D ACE gene polymorphism with regard to substrates of ACE as
indicated by:
a) The pressor and neurohormonal responses to angiotensin I
b) The hypotensive responses to ACE inhibitor drugs
2. To study prospectively aspects of the cough caused by ACE inhibitor drugs and
relationship to the I/D ACE gene polymorphism, in particular:
a) The effect of treatment with ACE inhibitors on the cough reflex in hypertensive subjects
b) The natural history of ACE inhibitor cough when treatment is withdrawn.
c) The effects ofACE inhibitors on the dermal wheal responses to bradykinin.
d) The dermal wheal response to bradykinin and relationship to ACE genoPpe .
c) The cough response to bradykinin and relationship to ACE genotype.





In this chapter I describe some of the techniques used in studies within this thesis. Three main
areas are covered:
i) the genotyping of an individual,
ii) the measurement of serum and tissue ACE activity,
iii) the method of cough reflex testing.
2.2 POLYMERASE CEIAIN REACTION (PCR) METHOD FOR THE DETECTION
OF THE ACE GENE INSERTION/DELETION POLYMORPHISM
Polymerase chain reaction(PCR) involves amplification of a specific sequence ofDNA by
specific sequences of nucleotide called primer, and the use of an enzyme that polymerises
DNA. The reaction requires relatively small amounts ofgenomic DNA and is considerably
faster than Southern blotting. First described by Rigat et al (1992) PCR detection of the ACE
gene polymorphism has now been performed in many laboratories. The region of the ACE
gene containing the variable site is amplified with two possible products. A 190 base pair
sequence in the absence of the insertion (ie a deletion) and 490 base pair sequence in the
presence of insertion.
This result thus allows three genotypes; homozygotes for the insertion (II), homozygotes for
the deletion (DD) and heterozygotes (ID). It has been suggested by Fogarty et al that
occasional mistyping might occur with those of genotype ID being classified as DD, and that
the addition of 5% dimethylsulphoxide prevents this (Fogarty 1994). My work had been
performed prior to this observation, and I retyped individuals retrospectively. There were no
changes in genotype allocation. Since I have completed my research, techniques such as
genot\ping an individual have become considerably faster. In 1991 it would have taken
several days to genotype a few individuals whereas in 1995 several thousand samples can be
processed within a few hours (CPDell 1995)
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2.2.1 Purification ofOligonucleotides
1. Oligonucleotides were synthesised on an Applied Biosystems 394 DNA/RNA
synthesiser, using phosphoramadite chemistry, in the University of Sheffield
Department of Medicine and Pharmacology.
2. Protecting chemical side groups were removed by incubation at 55°C for 8 - 15
hours in ammonia.
3. Ammonia was subsequently removed by drying overnight at 55°C.
4. Oligonucleotides were re-suspended in 1 ml of de-ionised water and then
quantitated by measuring UV absorbance (Beckman SP 64 spectrophotometer and
quartz cuvettes), using 25pg/ml as OD of 1.0 at 260 nm.
2.2.2 Rapidpreparation ofDNA from whole blood (lnnis et al 1990)
1. 50pl of whole blood (EDTA) was added to 0.5 ml TE buffer (lOmM Tris HCL pH
8, ImM EDTA)
2. Samples were then centrifuged for 10 seconds at 10,000g (Beckman microfuge 11)
and the resulting pellet was re-suspended in 0.5 ml TE buffer.
3. Stage 2,above was repeated twice. Thereafter the final pellet was re-suspended in
lOOpl ofK buffer (K buffer is lOOpg/ml proteinase K, 2.5ul Tween 20 and stock
buffer [50mM potassium chloride, 15mM Tris-base, 2.5 mM Mg CI2 pH 8.3 with
HCL]). Incubation was at 56°C for 45 min in order to digest the cells, then 10 min at
95 °C to inactivate the process.
4. The final solution was used at 1/10 of the final PCR volume.
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2.2.3 Polymerase chain reaction (PCR) methodfor the detection of the ACE gene
insertion/deletion polymorphism
The method of PCR detection of the ACE gene polymorphism described below was developed
in our laboratory from methods described by Saiki et al (1988) and Rigat et al (1992).
1. The sense oligonucleotide primer was 5'CTG GAG ACC ACT CCC ATC CTT
TCT 3' and the antisense primer was 5' GAT GTG GCC ATC ACA TTC GTC AGA
T 3'.
2. Reactions were performed in a final total volume of 50ml containing 10 pmol of
each primer, 5 mM MgCl2, 50 mM KC1, 10 mM Tris-HCl pH 8.4, 0.1 mg/ml gelatin,
0.5 mM of each dNTP (Pharmacia), 1 unit of Taq polymerase (Advanced
Biotechnologies, UK), 5 ml rapid extracted DNA and overlaid with 50 ml filter-
sterilised mineral oil. A water blank (control) was included.
3. Amplification was carried out in a Perkin-Elmer/Cetus DNA Thermal Cycler 480
with an initial 7 min denaturation followed by 30 cycles with steps of denaturation at
94°C for 1 min, annealing at 58°C for 1 min, and extension at 72°C for 1 min.
Samples were then stored at 4°C until removed from the machine.
4.PCR products were electrophoresed in 1% agarose submarine gels using
fxl74RF/HincII as a size marker. DNA was visualised by ethidium bromide staining





ID II ID II DDDD C M
Genotype
Figure 2.1 Example of an electrophoresis gel result following Polymerase chain
•eaction for ACE gene polymorphism 1= allele containing insertion, D=allele without
nsert. Results are shown for six individuals; ID (heterozygote), II (homozygote), and
3D (homozygote). C= blank control. M=molecular size marker.
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2.3 MEASUREMENT OF SERUM ACE
Angiotensin converting enzyme may either be measured as absolute levels or as activity of the
enzyme. The activity is more relevant when the effects of ACE inhibitor drugs are being
investigated.
2.3.1 Determination ofACE activity
Assays of ACE activity now involve chemical substrates, most commonly synthetic aryl-
oligonucleotides:
Hippuryl-glycyl-glycine (HGG) or benxoglycyl-glycyl-glycine is the original chemical
substrate. Several assays using HGG were developed involving dialysis of the sample and are
not often used now (Ryan et al 1977).
Hippuryl-histidyl-leucine (HHL) is the most commonly used substrate. Both histidyl-leucine
and hippuric acid are released on hydrolysis by ACE and may be estimated using various
techniques
Spectrophotometric determination (Cushman and Cheung 1971) is time consuming with
relatively poor sensitivity and precision.
Colorimetric method (Kwarts et al 1982) involves the condensation of hippuric acid with p-
dimethylamino-benzaldehyde and quantification.
Fluorimetric analysis (Friedland and Silverstein 1976) The release ofHL is measured by
spectrofluorimetry following addition of o-pthaldialdhyde. This method is rapid, simple and
very sensitive, and requires as little as 1ml of test serum. The assay has high reproducibility
and is more sensitive than spectrophotometric methods.
14
Radiochemical assay (Rohrbach 1978) using radiolabeled HHL. C-hippuric acid is
measured following incubation of substrate with enzyme. This assay provides good sensitivity
but is not suited to determination ofACE activity in serum or plasma.
FAPGG (furylacryloylphenylalayl-glycly-glycine) (Holmquist et al 1979) - the original
method was developed using enzyme purified from tissue. Ronca-Testoni (1983) adapted the
method for use with serum and several automated assays based on this method have been
described since. The use of FAPGG has advantages in that the change in absorbance may be
measured kinetically and hydrolysis is three times greater than with other substrates.
Therefore the assay time is shorter and the assay is more sensitive.
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2.3.2 Measurement of the ACEMolecule Direct measurement ofACE has been possible
since the preparation of specific anti-ACE antibodies. Alhenc-Gelas et al (1983) developed a
direct RIA for the determination of ACE levels in human serum using antisera to human lung
ACE raised in rabbits. Their method is sensitive enough to measure immunoreactive enzyme
molecules in human plasma in volumes of 50ml or less. Enzyme linked immunosorbent assay
(ELISA) techniques have been described but not used in clinical investigation (Lanzillo &
Fanburg 1982).
2.3.3 Measurement ofhuman serum ACE activity
The assay used in this thesis was that of Friedland & Silverstein (1976).
1. 20ml of test serum was added to 480ml buffered substrate at 37°C. Following
vortexing this was incubated for exactly 15 minutes. Buffered substrate was prepared
fresh as follows: 0.2 ml substrate (1.25mM Hippuryl-histidyl-leucine (FDTL) in
methanol) 1.0 ml phosphosaline buffer (0.5M di-potassium hydrogen phosphate,
1.5M sodium chloride, pH 8.3) 3.6 ml dH20
2. Simultaneously, 480 ml buffered standard was allowed to rest in the water bath
for the same period without serum. Buffered standard was prepared fresh as follows:
0.2 ml working standard (21.5mM, final cone, Histidyl-leucine (HL) in methanol) 1.0
ml phosphosaline buffer, 3.6 ml dFEo
3. Buffered substrate was also allowed to rest for the fifteen minutes without
samples added to act as blanks.
4. The reaction was then stopped by adding 2.9ml 0.28N NaOH to test samples,
standards, and blanks.
5. Serum was then added to both standards and blanks.
6. Then 200ml of the fluorescent reagent o-phthalaldehyde (15mM in methanol) was
added to all test tubes, and incubated at 37°C for 10 minutes.
7. This reaction was stopped by the addition of 400ml 3.ON Hydrochloric acid.
8. Serum proteins bound to o-phthalaldehyde are eliminated from the sample by
centrifugation at 1500 g for 10 minutes (International Equipment Company, USA,
Centaur-7R).
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Fluorimetry After 40 minutes the fluorescence was read with excitation at 368 nm and
emission at 500 nm (Perkin-Elmer Fluorescence spectrophotometer 1000, quartz cuvettes).
The fluorescence reaches a maximum after 20-30 minutes and is stable for about 1.5 hours
(Friedland & Silverstein 1976)
2.3.4 Calculation ofACE activity
Results were interpreted by the following formula:
(Test - Blank) x nmol HL in Std x Vol. sample x time
(Std - Blank)
Results are thus in nmolHL/ml/min.
Test, Blank, Standard = the fluorescent reading for each sample.
Volume sample = 20 ml for the routine assay.
Time = 15 minutes, for the routine assay.
Std = 10.32 nmol Histidyl-leucine for the normal control standard
A standard serum was produced from pooled serum from 50 healthy volunteers. This was
stored at -20°C, and at each assay a sample of this standard serum was run. The average
value of this serum had been determined by at least 10 previous assays to be 31.3 nmol/
ml/min, and at each procedure the final result of sample activity was adjusted for variation in
the result of standard serum activity.
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2.4 DETERMINATION OF TISSUE ACE
2.4.1 DirectMeasurement ofTissue ACE
Measurement of the biological activity ofACE in-vivo has been largely confined to studying
plasma ACE. It is much harder to examine membrane-bound (or thus tissue) ACE activity due
to the problem of dissociating the plasma component whilst maintaining live tissue. Until
recently there was also difficulty in accurately measuring angiotensin II levels. The dermal
responses to bradykinin, the cough response to bradykinin and the pressor responses to
angiotensin I provide biological models of ACE which include the main forms of the enzyme,
that is the membrane-bound form and the plasma form.
2.4.2 Dermal Responses as an IndirectMeasure ofTissue ACE
Subcutaneous injection of bradykinin produces a wheal and flare skin response (Basran
1982). When the ability of ACE to metabolise bradykinin is blocked by ACE inhibitor
treatment the response to bradykinin given intradermally increases (Ferner et al 1987, 1990).
Thus intradermal bradykinin administration has become an accepted method of assessing
dermal ACE and thus membrane bound ACE activity in vivo (Ferner et al 1987). It is of
course not possible to separate the effects of dermal ACE from serum ACE in-vivo. ACE,
apart from inactiving bradykinin, also catalyses the metabolism of substance P (Lindgren et al
1987). Bradykinin stimulates sensory neurones containing substance P, thereafter this
stimulates mast cells resulting in histamine release (Widdicombe 1980, Lindgren 1989). A
sufficient dose will send orthodromic impulses to the spinal cord to relay sensory information
such as itching, pain and burning via C fibres. Antidromic impulses produce a flare, and the
increased permeability in the widely dilated blood vessels result in tire local oedema called the
wheal. The wheal can be measured according to its area or thickness (Ferner 1987, Ferner
1989, Chapman 1977). The metabolism of histamine is non-kininase dependent and the
dermal responses to histamine are not affected by ACE inhibitor treatment (Anderson 1990).
The dermal responses to bradykinin and histamine were examined in chapter 8, when
examining possible differences between subjects of different ACE genotype. The responses to
bradykinin and substance P were examined in chapter 6 to determine the pattern of changes in
tissue ACE when an ACE inhibitor drug was withdrawn.
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2.4.3 Wheal andflare response to intradermal vasoactive agents (Bradykinin, Histamine
and Substance P)
1. Solutions were prepared fresh from stock solutions on each test day and stored on ice.
Sodium chloride (0.9%) was used to make up each dilution.
2. A wheal and flare response was produced by a single 0.1ml intradermal mjection in a grid
pattern of eight injection sites on the anterior aspect of the right forearm, using a 0.4 mm
diameter needle. Injections were made at least 3 cm apart.
3. The cutaneous reaction induced by intradermal injection of the vasoactive agents was
evaluated by measurement of the wheal area.
4. The response was measured at 15 minutes by drawing round the wheal in ink and
transferring the image to graph paper using adhesive cellophane tape. The area of response
was measured by digitalised computer planimetry using a Cherry computer bit pad, using
software designed by P. Armstrong (Computing Services, University of Sheffield) using the
mean of three measurements.
2.4.4 Intravenous infiision ofangiotensin 1
Angiotensin I causes a dose-dependent pressor effect when infused intravenously (Belz et al
1987, Wellstein et al 1987, Essig et al 1989) with steady-state levels of blood pressure
achieved within 3 minutes (Belz et al 1987). Factors important in determining the blood
pressure response are race and sodium balance (Joubert et al 1990). I examined the pressor
response to angiotensin with respect to ACE genotype in chapter 3 with the purpose of
establishing whether vascular tissue ACE might differ according to genotype.
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2.5 ASSESSMENT OF COUGH AND COUGH REFLEX TESTING
2.5.1 Measurements ofSubjective Cough. In chapters 5 and 6 the symptom of cough is
measured by the use of questionnaires and visual analogue scales.
2.5.1.1 Questionnaire in assessment of cough The self-administered questionnaire
used in the studies on cough was validated by Fletcher and consists of a list of symptoms
which are graded by the subject (Appendix 1). The symptoms examined were: dry mouth,
cramps, dry cough, racing heart, heartburn, headache, sore throat, nocturia, facial flushing,
voice changes, diarrhoea and stuffy' nose. The severity of these symptoms was graded as:
not at all (0), a little (1), moderately (2), quite a bit (3) or extremely (4) (Fletcher 1990, Yeo
1991, Lacourciere 1994).
The second part of the questionaire invited further details regarding the presence or absence of
two symptoms: headache and cough. Questions on headache preceded those on cough. The
inclusion of detailed questions on headache and other symptoms aimed to reduce the bias
towards reporting of cough.
In the study examining the cessation of cough a diary relating to the nature of the cough was
completed by the patient each day. This consisted of six questions concerning nocturnal
severity, frequency, daytime severity, throat soreness, husky voice and stuffy nose. These
were graded in the same way as the questionnaire above. A similar questionnaire was used to
measure night time cough (Appendix 2).
2.5.1.2 Visual analogue scales in assessment of cough
Visual analogue scales have been used in several previous studies examining cough with ACE
inhibitors (Fletcher 1990, Lacourciere 1994, Yeo 1991). Severity and frequency of cough
were measured by two of these validated visual analogue scales. They consisted of 10 cm lines
with the following statements at opposing ends: (I never cough -1 am always coughing);
(Cough has been absolutely no trouble to me- my cough has been as bad as it could possibly
be)
(Fletcher 1990, Appendix 3).
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2.5.1.3 Definition of ACE inhibitor cough
The criteria for diagnosis of ACE inhibitor cough during the prospective study (Chapter 5)
were (a) a new onset of cough during ACE inhibitor treatment (b) persistence of the cough for
longer than three weeks and (c) no other identifiable cause. These clinical criteria have a
positive predictive value of 95% for ACE inhibitor cough (Yeo 1991). The same criteria were
applied to the patients who were examined with cough and in who the ACE inhibitor was
discontinued (chapter 6). They also applied to those patients with ACE inhibitor cough
genotyped for the I/D ACE polymorphism (chapter 9).
2.5.2 Methods ofassessing the cough reflex
Several methods have been used to study the cough reflex. There is general agreement that
capsaicin and citric acid are the most useful tussive agents for cough reflex testing but less
agreement exists about dose and the method of administration. Capsaicin (8-methyl-N-
vallenyl-6-nonenamide), a purified extract of chilli peppers, is the most commonly used
tussive agent directly stimulating bronchial C-fibres (Winning et al 1986). Stimulation of C-
fibres by capsaicin induces cough and transient bronchoconstriction lasting less than one
minute (Collier & Fuller 1984) as shown by single nerve fibre recordings (Coleridge &
Coleridge 1984). Citric acid (Pounsford & Saunders 1985, Morice 1987), and continuous
inhalation of distilled w ater (Morice 1987) have also been used to stimulate cough. They
suffer from the disadvantage of tachyphylaxis, and it is thus difficult to construct dose-
response curves (Morice 1992).The delivery systems used to administer the tussive agent have
varied considerably. Initial methods consisted of continuous inhalation from a one litre dead
space supplied via a nebuliser with subjects inhaling for between 30 and 60 seconds, whilst
measuring the cough response (Collier & Fuller 1984, Pounsford & Saunders 1985, Morice
1987). Recently single dose inhalation has been used, either via a Mefar breath-activated
dosimeter, or De Vilbiss No. 40 nebuliser. Both of these methods have been extensively
validated (Fuller & Choudry 1987, Morice 1987, Foster 1991).The method of administering
doses of tussive agents either as incremental doses (Pounsford & Saunders 1985, Morice
1987), or in random order (Fuller & Choudry 1987, Foster 1991), appear to produce equally
valid and reproducible results for cough reflex testing.
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2.5.3 Interpretation ofcough data
The cough response is not linear. Doubling the stimulus causes less than a doubling of the
response (Widdicombe 1980), and analysis of cough dose- response curves to stimuli such as
capsaicin poses interesting mathematical problems. The raw cough response data derived by
tussive challenge are not normally distributed, and nonparametric tests such as the Wilcoxon
signed rank test and Friedman's non-parametric analysis have been used. These statistical
tests are useful when comparing related or matched samples to examine whether cough
response changed significantly within subjects under the test condition (Pounsford 1985).
The measurements usually taken when cough testing is done include the following:
i) The number of coughs per minute.
ii) The total number of coughs for all doses, the total cough response (TCR). This is an
approximation of the area under the curve of the dose response and is a measure of the overall
sensitivity- during cough challenge (Foster 1992).
iii) The lowest dose to cause 1, 2 or 5(or more) coughs; the D1 (Foster 1992), D2, or D5
(Collier & Fuller 1984, Morice 1987) respectively. The D2 and D5 have been used as
measures of the cough threshold and sensitivity (Collier & Fuller 1984, Choudry 1990).
Another method of analysing cough responses is to determine whether there is a shift in the
dose-response curve to the left or right on the x-axis, or to examine the dose required to attain
a particular cough response, rather than analysing cough scores. In these techniques the dose
used is log transformed and then parametric tests can be performed. Parallel line bioassay is
an example of this method of analysis and is now described.
2.5.4 Parallel line bioassay in cough reflex testing
In this thesis the capsaicin dose response curves and skin responses to bradykinin were
analysed using a parallel line bioassay method (Armitage and Berry 1987). This technique
estimates the relative potency, with 95% confidence intervals, of capsaicin on the cough
response in subjects at different timepoints. The relative potency is a measure of shift of the
dose-response curve to left or right when a paired comparison is made. Thus lower relative
potency estimates indicate reduced sensitivity to the capsaicin. For each analysis the slope
should be significant and the model has to satisfy rules for parallelism and linearity. This
technique is a form of analysis of variance and when used the doses of drug given are log-
transformed.
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2.5.5 Cough testing with capsaicin (Foster et al 1991).
This method involves the inhalation of single doses of capsaicin solution administered in a
random order.
Preparation ofcapsaicin solutions
0.125 ml of the concentrated stock solution was diluted with 2.375 ml sodium chloride (0.9%)
to give a working solution of 5 mmol/ml. This was made into solutions for inhalation by
further serial dilutions with saline. The doses delivered per 0.0025 ml delivery were thus in log
incremental doses from 0.025 - 6.25nmol.
Method ofadministration
1. One ml of each solution was placed in a separate nebuliser.
2. Subjects inhaled slowly and deeply over 1-2 sees. One delivery from the nebuliser
was administered at the beginning of inspiration.
3. The number of coughs produced during the one minute after challenge were
recorded.
4. Challenges were given at two minute intervals.
5. The number of coughs at each dose were recorded by an examiner blinded to either
the subjects genotype in chapter 7 or to the drug taken in chapter 5.
2.5.6 Cough reflex testing with bradykinin
The cough response to bradykinin is examined in chapter 7. When previously studied in man
bradykinin caused a bronchoconstrictor response in those with asthma but not in healthy
individuals (Simonsson 1973, Fuller 1987). Cough unrelated to any change in airways
calibre, was observed, to a varying extent in these and other studies (Dixon 1987, Choudry
1989, Ichinose 1992).
Bradykinin (Sigma,UK) in 10% ethanol in saline, was administered in the following doses:
0.125 mg/ml, 0.25 mg/ml, 0.5mg/ml, lmg/ml, 2mg/ml, 4mg/ml. Dilutions were made with
0.9% sodium chloride.
2.5. 7 Measurement ofrespiratoryfiinction
Respiratory function including forced expiratory volume (FEV1), forced vital capacity (FVC)
and peak expiratory flow rate (PEFR) was measured using a Vitalograph-compact






PRESSOR AND HORMONAL RESPONSES
TO ANGIOTENSIN I INFUSION
IN HEALTHY SUBJECTS
3.1 INTRODUCTION
An individuals genotype for the I/D polymorphism in the ACE gene gives a strong indication
of the serum ACE for that person. The clinical relevance of this finding was uncertain until it
was suggested that the ACE genotype was linked to vascular disease. The deletion (D) allele
has been suggested as a risk factor for myocardial infarction (Cambien 1992), ischaemic and
dilated cardiomyopathy (Raynolds 1993), and the development of left ventricular hypertrophy
(Schunkert 1994). The mechanism by which the D allele may exert such detrimental effects is
unknown but could be through an enhanced rate of production of angiotensin II resulting in
increased pressor and trophic cardiovascular responses. The enhanced production of
angiotensin could be related to the concentration of serum ACE or the activity of ACE bound
to the vascular endothelium (Swales 1993).
To my knowledge the expression of ACE at the vascular endothelium, another form of tissue
ACE had not been examined. I have studied this indirectly by examining the response to
intravenous infusion of angiotensin I. Angiotensin I causes a dose-dependent pressor effect
when infused intravenously (Belz et al 1987, Wellstein et al 1987, Essig et al 1989) with
steady-state levels of blood pressure achieved within 3 minutes (Belz et al 1987). Factors that
might be important in determining the blood pressure response are race and sodium balance
(Joubert et al 1990).
3.2 AIMS
1. To determine whether pressor or neurohormonal responses to angiotensin I infusion differ in
healthy subjects homozygous for either the I or D allele.
3.3 METHODS
3.3.1 Subjects
Sixteen healthy Caucasian men aged 26 years (range 19-36) were selected to provide equal
numbers of the two genotypes DD (n=8) and II (n=8). Supine blood pressure was measured
on three occasions over one week and those with a mean diastolic greater than 80 mmHg were
excluded. All had normal serum creatinine, electrolytes and electrocardiograph. Subjects




(Figure 3.1) Subjects attended at 0900h having avoided added salt and foods with a high salt
content for three days prior to the study, and having refrained from food, smoking, caffeine
and strenuous exercise for 12 hours. Urinary sodium excretion over 24 hours was measured
immediately prior to the infusion. Sodium chloride 0.9% was infused intravenously for a 30
minute baseline period at 48ml/hr via an IYAC pi000 pump whilst subjects lay supine.
Angiotensin I was prepared in the hospital pharmacy as a sterile solution containing 50 pg/ml
in 0.9% sodium chloride then diluted to concentrations of 1.2 pg/ml and 4pg/ml. Angiotensin
I was infused at an initial rate ofO.lpg/min and increased to 0.3, 0.9, 1.8, 3.0, 4.0, 5.0 and
6.0 pg/min at 3 minute intervals, or until a rise in diastolic pressure of 25 mmHg was
achieved. Blood pressure and heart rate were measured 30, 15, 10, 5 and 0 minutes before the
angiotensin infusion, during the final 30 seconds of each 3 minute infusion period, and at 10
minute intervals after the infusion was discontinued. Blood was taken for serum ACE activity
and plasma renin, angiotensin II and aldosterone concentrations before and at the end of the
angiotensin I infusion. Identical syringes were used during the baseline and angiotensin I
infusion periods so that subjects were unaware when the angiotensin infusion began. The
investigators were blind to the genotype of the subject.
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Figure 3.1 Diagrammatic overview this study where the pressor response to
angiotensin I was examined according to ACE genotype in healthy subjects.
Fast, avoid strenuous exercise, 2100
No cafifiene,tobacco,alcohol I
I
Start of in-patient study period 0830
Infusion begins now 0900
sodium chloride (0.9%) 4
at 48ml/hr.
(Subject blinded to infusion) I
I
Infusion of angiotensin / begins 0930
at initial rate of 0.1 pg/min




When diastolic blood pressure I
has increased by at least 25mmHg I





Continued observation for 30 mins I
I
End
Explanation to subject, cannula
insertion
Pulse and BP recording taken
at 0900, 0915, 0920, 0925
Pulse and BP recording taken
at 0930, 0933, 0936, 0939, 0942
(ie prior to dose increase)
Blood taken for neuro-hormonal
measurement at 0930
Blood taken for neuro-hormonal
measurement at cessation of
angiotensin I
Pulse and blood pressure
recording taken




ACE genotype was determined by polymerase chain reaction as described in chapter 2. Serum
ACE activity was measured by fluorimetric assay with units expressed as nmol of histidyl-
leucine produced per ml of sample per minute as previously described. Plasma renin (Millar
1980), angiotensin II (Morton 1985) and aldosterone ('Coat-a-count' Kit, Diagnostic Products
Corporation) concentrations were measured by radioimmunoassay. Blood pressure and heart
rate were measured by a Dinamap semi-automated recorder.
3.3.4 Endpoints
The principal endpoints to be examined were the doses of angiotensin I which lead to an
increase in blood pressure by 25 mmHg. These were the R(d)25> R(s)25 (f®-25)- '^ie
R(d)25 was the rate of angiotensin I infusion which caused a 25 mmHg rise in diastolic blood
pressure; and the R(s)25 was the rate of infusion at which a 25 mmHg rise in systolic pressure
occurred. Changes in heart rate (HRgf) were analysed at the time the R(d)25 was attained.
3.3.4 Statistical analysis
Using a published standard deviation for the diastolic pressor response to angiotensin I
infusion in Caucasian subjects (Joubert 1990) it was calculated that eight subjects were
required in each group to detect a difference in R(d)25 between groups of 1,75pg/min of
angiotensin I with 80% power and a=0.05. After logarithmic transformation of the rate of
infusion of angiotensin I to approximate a linear dose response the R(d)25 and R(s)25 were
interpolated from individual responses. Fifteen subjects achieved a 25 mmHg or greater
increase in diastolic blood pressure, but one achieved a rise of only 21 mmHg and had the
R(d)25 calculated by extrapolation. The R(d)25 an^ R(s)25 are expressed as geometric
means of the responses for each genotype, and the difference between genotypes is expressed
as the ratio of the geometric means with 95% confidence intervals for this ratio. Unpaired t-
tests were used to investigate differences in blood pressure, heart rate and neurohormonal
responses between the groups at baseline and after angiotensin 1 infusion. Paired t-tests were




(Table 3.1). Age, weight, baseline blood pressure, heart rate and 24 urinary- sodium excretion
were similar in the two groups. As anticipated there was a significant relationship between
ACE genotype and serum ACE activity at baseline, with mean serum ACE 25.0 nmol/ml/min
in group DD and 13.1 nmol/ml/min in group II (p<0.02). There were no significant
differences in baseline plasma renin and aldosterone levels between the genotypes. Baseline
angiotensin II levels were higher in the DD subjects (7.0 pg/ml) than II subjects (4.7 pg/ml),
and this difference approached significance (difference DD-II = 2.3pg/ml, 95% C.I.: 0.0 to
+4.6, p=0.07).
Table 3.1 Baseline data for healthy male volunteers according to ACE genotype;
n=8 for each group (mean ± se).
DD II
Age (years) 26.7(2.1) 24.9 (1.7)
Weight (kg) 70.7 (2.0) 76.0 (3.2)
SBP (mmHg) 123.5 (2.1) 121.0 (2.0)
DBP (mmHg) 70.8 (2.1) 69.2 (1.8)
Heart rate (bpm) 58.4 (2.0) 62.3 (2.1)
Urinary sodium (mmol/24h) 130.4 (17.7) 111.0(16.1)
Plasma Renin Concentration(u/ml) 13.4 (2.5) 11.5 (2.7)
Plasma Aldosterone (ng/100ml) 11.7 (1.3) 11.0(1.2)
Plasma Angiotensin II (pg/ml) 7.0 (1.0) 4.7 (0.4)
Serum ACE activity* nmol/ml/min 25.0 (1.7) 13.1 (0.6)
* p<0.02 for difference between groups,
3.4.2 Changes in bloodpressure
(Table 3.2, Figure 3.1). The geometric mean rate of infusion of angiotensin I required to
achieve the R(d)25 was 2.53pg/min in II subjects and 2.67pg/min in DD subjects (ratio of
doses (II:DD) = 0.95; 95% CI 0.44 to 2.02, p>0.05). The equivalent rates of infusion for
systolic blood pressure (R(s)25) were 4.47pg/min in II subjects and 3.39pg/min in DD
subjects (ratio of doses (II:DD) = 1.32; 95% CI for ratio 0.49 to 3.56, p>0.05).
3.4.3 Changes in heart rate
(Table 3.2, Figure 3.2). There was a significant difference between the groups in the
chronotropic response to angiotensin I infusion. At the time of the R(d)25 the mean change
from baseline heart rate was +1.2 bpm for DD subjects and -9.5 bpm for II subjects (Diff II-
DD= 10.7 bpm; 95% CI: 6.7 to 14.8; p=0.01).
3.4.4 Changes in serum ACE activity andplasma renin, angiotensin II and aldosterone
concentrations
(Table 3.2). There was a rise in serum ACE activity after angiotensin I infusion in all
subjects but there was no difference in this response between subjects of differing genotypes.
There was no change in the mean plasma renin concentration in response to angiotensin I
infusion. Serum aldosterone and angiotensin II levels rose as expected but there was no
difference in responses between groups. There were also no differences between the genotypes
when these measurements were calculated as the unit change per pg angiotensin I infused (i.e.
the sensitivity to angiotensin I).
Table 3.2. (i) Rate of angiotensin I infusion to achieve a 25 mmHg rise in diastolic (R(d)25)
and systolic (R{s)25) blood pressure and (ii) changes in heart rate (HR2s) and neurohormonal
parameters from baseline after a 25mmHg rise in diastolic blood pressure during angiotensin I
infusion in DD and II subjects.
II DD
(>) Geometric Geometric Ratio of doses 95% C.I. of
mean mean (II:DD) ratio
R(d)25 (Eg/n™) 2.53 2.67 0.95 0.44 to 2.02
r(S)25 (Eg/min) 4.47 3.39 1.32 0.49 to 3.55
(ii) Mean (se) Mean (se) Difference 95% CI for
(II-DD) difference
HR25 (bpm) -9.5 (3.1) + 1.2 (2.1) -10.7* -6.7 to-14.8
Plasma Renin (uU/ml) -2.1 (1.2) -0.4 (1.0) -1.7 -5.1 to +1.6
Serum ACE (nmol/ml/min) + 15.7 (0.7) +30.1 (2.3) -14.4* -9.3 to-19.5
Angiotensin II (pg/ml) + 181.0 (24.0) + 180.0(9.0) + 1.0 -53.6 to +55.6
Aldosterone (ng/ml) + 10.3 (2.3) + 11.4 (3.4) -1.1 -9.8 to +7.6
*p = 0.01
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3.4.5 Changes in bloodpressure v initial serum ACE.
There was no relationship between the change in blood pressure as determined by

































Figure 3.2 The dose of angiotensin I (pg/min) required to increase diastolic bp by




Figure 3.3 The heart rate (bpm) at baseline (a) and at maximal angiotensin 1
infusion rate required to increase diastolic bp by 25mmHg (b) in healthy male subjects
according to genotype (n=8 for each genotype).
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3.5 DISCUSSION
The strong relationship between ACE genotype and serum ACE activity was confirmed in this
study. As expected angiotensin I caused a pressor response, increased plasma angiotensin II
and aldosterone concentrations, but caused no change in plasma renin concentration.
However, neither the pressor nor the hormonal responses differed significantly between the
two genotypes despite a near fourfold higher mean serum ACE level in the DD subjects. The
only significant difference in response between the genotypes was in heart rate. There was an
increase in serum ACE activity shown in this study. This unusual and unexpected finding is
difficult to explain but is most likely to represent some interference in the assay technique
rather than enzyme induction.
Overall these results show no evidence that the sensitivity of the renin-angiotensin-aldosterone
system to angiotensin I varies with serum ACE level or I/D genotype. However although the
geometric means for the R(d)25 were similar, with a ratio of 0.95, the 95% confidence
intervals show that the study had insufficient power to exclude ratios between 0.44 (DD>II)
and 2.02 (II>DD). This relatively low power was not expected, and was due to much greater
variability in the pressor response to angiotensin I infusion using this protocol (Figure 1) than
was anticipated from the data of Joubert and Brandt (Joubert 1990). The reasons for this are
not clear, but as shown in Figure 1 there was one outlying subject in the II group. However
even if this subject was excluded the ratio of geometric means (II:DD) was 0.78, with 95%
confidence intervals of 0.39 to 1.55, so that there was still no significant difference in the
genotypes.
While my study was in progress a similar study of the pressor sensitivity to angiotensin I
infusion in relation to ACE genotype was reported (Ueda et al 1994). Ueda et al showed a
significant increase in pressor sensitivity to angiotensin I infusion in 10 healthy normotensive
DD men compared to 10 II men. The II:DD ratio for the rates of infusion of angiotensin I
required to achieve a 20mmHg rise in mean arterial pressure in their study was 1.68. I
recalculated my data in an analysis similar to that of Ueda et al, correcting for body weight
and using as the end point a 20mmHg rise in mean arterial pressure. Analysed thus the ratio of
infusion rates II:DD was 1.12 with 95% CI 0.65 to 1.92. By contrast Menard et al found no
relation between diastolic blood pressure response and genotype (Menard 1995) using similar
methodology to my study. Thus this study does not confirm their positive finding, although it
had insufficient power to exclude a difference of the magnitude reported.
The only significant difference between the two genotypes was in the chronotropic response to
angiotensin I infusion. Subjects of II genotype exhibited bradycardia averaging 9 beats per
minute associated with a 25 mmHg rise in diastolic pressure, whereas DD subjects showed no
change in heart rate. That subjects of DD genotype exhibited less heart rate slowing than the
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II subjects at a similar pressor response could imply altered baroreceptor sensitivity between
the genotypes. Angiotensin II is known to inhibit the reflex slowing of heart rate to a rise in
arterial pressure (Smyth 1969). In chapter 4 I will describe the finding of no difference in the
chronotropic response to a single oral dose of enalapril in healthy subjects of differing ACE
genotype. However as I found no evidence of other differences in haemodynamic responses in
homeostasis or in the rate of production of angiotensin II, between II and DD subjects the
difference between genotypes in chronotropic response to angiotensin I may be a chance
observation, however further study of cardiovascular reflexes in relation to ACE genotype
may be of interest.
The conversion of angiotensin I to angiotensin II is not the rate limiting step in the renin-
angiotensin cascade (Danser 1992) and marked inter-individual differences in serum ACE
levels may be of little or no importance.
In summary:
• The effects of incremental infusion of angiotensin I on pressor and hormonal responses in
relation to the ACE genotype were compared in healthy men of genotype DD and II.
• Serum ACE activity differed significantly between the genotypes with significantly higher
mean values in DD subjects than II subjects. Serum ACE also increased during the study
but this did not differ between genotypes.
• The mean infusion rates of angiotensin I required to achieve a 25 mmHg rise in diastolic
pressure [R(d)25] were 2.53 pg/min in II subjects and 2.67 pg/min in DD subjects (ratio
of infusion rates 0.95; 95% CI 0.44 to 2.02, p>0.05).
• At the time ofR(d)25, changes in heart rate from baseline were +1.2 bpm for DD subjects
and -9.5 bpm for II subjects (Diff II-DD= 10.7 bpm; 95% CI: 6.7 to 14.8; p=0.01).
• There were no differences in plasma renin, angiotensin II and aldosterone responses to
angiotensin I infusion between the DD and II genotypes.
• No differences in blood pressure or renin-angiotensin-aldosterone system responses to
infusion of angiotensin I related to the ACE gene polymorphism were shown, but the study
has insufficient power to exclude with certainty such differences. There was a significant




EFFECT OF A SINGLE DOSE OF ENALAPRIL
ON SERUM ACE ACTIVITY
AND BLOOD PRESSURE
IN HEALTHY SUBJECTS
OF DIFFERENT ACE GENOTYPE.
4.1 INTRODUCTION
ACE inhibitor drugs such as enalapril are used widely in the treatment of hypertension and
heart failure. The initial response to ACE inhibition is probably due to a combination of
factors including vagal responses and pre-existing activation of the renin-angiotensin system
(Squire 1996). ACE inhibitors reduce serum ACE activity, and some studies have shown a
relation between this reduction in serum ACE activity and falls of blood pressure (Johnston
1983). Through its strong association with serum ACE activity the ACE genotype could
therefore influence or predict the response to ACE inhibitors.
4.2 AIMS
The purpose of this study was to examine:
1. The relation ofACE genotype to the acute effects of the ACE inhibitor enalapril on serum
ACE activity and blood pressure




Twenty-seven healthy normotensive men ofmean age 27 years (range 20-46) were selected to
provide equal numbers of the three genotypes, ie n=9 for each of the genotypes DD, ID and
II. They gave written informed consent to the study which was approved by the district ethics
committee. Five of these subjects had also taken part in the study in chapter 3
4.3.2 Study design
Each subject was given a single oral dose of enalapril lOmg in an open parallel group
comparison of the three genotypes. Subjects attended at 0830 h having refrained from
smoking, caffeine or strenuous exercise for 12 hours. Otherwise they had followed their
normal diet prior to the study, and specifically sodium intake was not controlled or perturbed.
They lay supine for 30 min before receiving a single 10 mg dose of enalapril orally. They
were semi-recumbent for 6h after taking enalapril and remained fasting except for a standard
meal 4h after enalapril. Blood pressure and heart rate were measured at 30, 15, 10, 5 and 0
min before enalapril and at 20 min intervals for 6 h post-dosing. Serum ACE activity was
measured at 0 (pre-enalapril), 2, 4, 6 and 24 h.
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4.3.3 Measurements
ACE genotype was determined by polymerase chain reaction described in chapter 2.2. Serum
ACE activity was measured by fluorimetric assay with units expressed as nmol of histidyl-
leucine produced per ml of sample per minute (chapter 2.3.3). Blood pressure and heart rate
were measured by a Dinamap semi-automated recorder (Silas 1980) taking the mean of
duplicate measurements at each time point.
4.3.4 Statistical analysis
Changes in blood pressure and serum ACE activity from baseline (pre-enalapril) values were
compared between the three genotypes by one-way analysis of variance, and 95% confidence
intervals were calculated for differences between DD and II genotypes. The relationship
between changes in serum ACE activity and blood pressure was examined by product-moment
correlations. Blood pressure data were log transformed to normalise the distribution.
4.4 RESULTS
Comparability ofgroups (Table 4.1). Subjects from the three genotypes were of similar age
but differed as regards weight, with ID subjects significantly heavier than those of DD or II
genotype. Average baseline blood pressure was similar in the three groups. As anticipated
(Rigat 1990) there was a significant relation between ACE genotype and serum ACE activity
at baseline (p<0.02 between groups), with DD subjects having mean serum ACE activity
56% higher than that of II subjects (Figure 4.1). The ACE genotype accounted for 40% of
the between-subject variance in serum ACE activity at baseline.
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Table 4.1. Baseline data for 27 healthy male volunteers before enalapril dosing according to
ACE genotype (Mean ±SD )
DD ID II
Age (yr) 23.8 (4.1) 27.3 (6.6) 28.4 (8.0)
Weight (kg) * 71.4 (5.5) 78.3 (8.5) 69.9 (6.5)
SBP (mmHg) 128.2 (5.6) 127.6(10.0) 128.0(5.6)
DBP (mmHg) 72.7 (7.4) 72.7 (9.3) 68.1 (9.1)
MAP (mmHg) 91.2 (5.7) 91.0(8.7) 85.6 (7.4)
Heart rate (bt/min) 66.6(8.3) 65.0(10.5) 63.7(8.0)
ACE activity**
(nmol/ml/min)
40.7 (9.3) 31.8 (6.4) 26.1 (6.1)
* p=0.04; **p=0.017 for difference between groups
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4.4.2 Changes in serum ACE activity
(Table 4.2, Figure 4.1). In all subjects serum ACE activity was reduced substantially 2 h after
enalapril, and remained below baseline levels at 24 h. The serum ACE responses to enalapril
differed significantly between the ACE genotypes, with the reduction significantly larger in
DD than II subjects at 2, 4, and 6 h (Table 4.2, Fig 4.1). The difference between genotypes
was no longer present at 24 hours (Table 4.2). The ACE genotype continued to explain
approximately 40% of the between-subject variance in serum ACE activity at each time point
after enalapril. The percent reduction in baseline ACE activity after enalapril showed a
different pattern, with larger proportional falls in II than DD genotype subjects, but
differences between the groups were small (Table 4.2).
Table 4.2 Mean (SE) changes at 2, 4 and 6 hours in serum ACE and mean arterial
blood pressure (map) for each genotype








2 h 27.9 (3.5) 22.5 (2.9) 18.9(1.7) ns 9.0 0.7 - 17.2
4 h 32.3 (2.7) 26.1 (1.9) 21.6 (1.8) 0.01 10.7 3.8 - 17.6
6 h 31.2 (2.7) 25.5 (1.9) 21.5 (1.7) 0.02 9.7 2.8 - 16.6




2 h 67.5 (4.4) 68.6 (6.3) 72.9 (3.7) ns -5.4 -17.6-(6.8)
4 h 79.3 (1.2) 81.8 (1.9) 82.8 (1.0) ns -3.5 -6.7 - (-0.3)
6 h 76.5 (1.8) 80.3 (1.9) 82.6 (1.1) 0.04 -6.1 -10.5 -(-1.7)




2 h 4.6 (3.0) 1.7(3.0) 5.6 (3.5) ns -1.0 -10.7-8.7
4 h 8.8 (2.2) 4.9 (3.9) 9.1 (2.9) ns -0.3 -8.0 - 7.4
6 h 12.9(2.9) 8.5 (3.6) 10.6(3.5) ns 2.3 -7.4 - 12.0
* Significance of difference between the groups
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4.4.3 Changes in bloodpressure. (Figure 4.2) The average fall in mean arterial pressure in
all subjects was 7 mmHg (8%) in the 6 hours after enalapril. There were no significant
differences between the genotypes for blood pressure response, and in particular no consistent
trend for the enalapril response to be larger or smaller in DD compared to II subjects (mean
difference DD-II: 0.7 mmHg). The 95% confidence interval makes unlikely differences in
response between the genotypes larger than 4.1 mmHg (DD>II) or 5.5 mmHg (II>DD).
4.4.4 Changes in serum ACE activity v blood pressure. In all 27 subjects the fall in mean
arterial pressure averaged over 6 hours after enalapril did not correlate with initial ACE















































Figure 4.1 Serum ACE activity at baseline (a) and 6 hours after treatment with
enalapril 10 mg (b), related to ACE genotype. Note different scale between baseline









































































Figure 4.2 Changes in systolic blood pressure (2a) and diastolic blood pressure (2b)
after treatment with enalapril 10 mg related to ACE genotype, >=DD genotype, □ =
II genotype and A =ID genotype (mean ± se)
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4.5 DISCUSSION
This study confirms the relationship between ACE genotype and serum ACE activity (Rigat
1990), with the ACE genotype accounting for 40% of between-subject variance and DD
subjects having serum ACE activity 56% higher than those of II genotype. As might be
expected subjects with genotype DD, who had the highest serum ACE activity initially, had
significantly larger falls in serum ACE activity at 2,4 and 6 hours after lOmg enalapril when
compared to the other genotypes. This difference was no longer evident after 24 hours. In
percentage terms subjects ofgenotype II, who had the lowest serum ACE activity initially,
actually showed the largest fall in serum ACE activity, although the differences between the
three genotypes were small. Enalapril did not abolish the difference between genotypes in
serum ACE activity, with residual serum ACE remaining significantly higher in DD than II
subjects at each time point. Despite enalapnl treatment the ACE genotype continued to
account for about 40% of the between-subject variance in serum ACE, and subjects of
genotype DD had serum ACE values approximately twice those of genotype II.
Johnston et al. showed a close relation between reduction in serum ACE activity and the fall in
blood pressure in hypertensive subjects after a single 10 mg dose of enalapril (Johnston 1983).
In the present study blood pressure response did not correlate with percent or absolute
reduction in ACE activity, or with initial serum ACE. There was no significant difference in
hypotensive response between genotypes. Although subjects of DD genotype had higher serum
ACE activity initially, and larger falls in serum ACE in response to enalapnl. their blood
pressure response was not different from those of the other genotypes. Shown by the 95%
confidence intervals the study had sufficient power to exclude differences, in mean arterial
pressure responses larger than 5.5 mrriHg (II>DD) or 4.1 mmHg (DD>II). I examined healthy-
subjects in normal sodium balance, who have only small blood pressure reductions with
enalapril (Todd 1986). and these results do not preclude the possibility that the ACE genotype
may predict the response of hypertensive patients or those with heart failure to ACE inhibitor
treatment. In those with chronic heart failure the chronic response does not appear to differ to
the acute response to ACE inhibitor (Squire 1996).
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Some recent work published at present in abstract form also examined whether there was a
relationship between genotype and blood pressure responses. O'Kane et al (1996) examined
the responses in salt-deplete healthy subjects using 5mg of enalapril.
No significant difference between the groups was found however confidence intervals are not
given to allow determine the certainty of this conclusion. Using different methodology Ueda et
al (1996) examined the responses to enalaprilat in healthy subjects who had been infused with
angiotensin I. Their work suggests that subjects of genotype II might have greater responses to
enalaprilat however the data published shows wide confidence intervals for difference from
placebo. The confidence intervals for the difference in response between the genotypes are not
shown in the abstract form and it will be interesting to study the full published work. Thus
this area of research has attracted more attention since my initial study but as yet it remains
uncertain as to whether true conclusions can be drawn.
In summary:
• The ACE genotype influences serum ACE activity under normal conditions and after a
single oral dose of enalapril, and also predicts the acute responses of serum ACE acthity
to a single dose of enalapril.




PROSPECTIVE CONTROLLED STUDY OF COUGHWITH
ENALAPRIL:
MEASUREMENT BY QUESTIONNAIRE, VISUAL ANALOGUE
SCALES,
AND
CHANGES IN RESPONSE TO INHALED CAPSAICIN.
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5.1 INTRODUCTION
As discussed in chapter 1 cough due to ACE inhibitor is much more common than initially
thought. Most estimates of its prevalence were from retrospective studies or cross-sectional
surveys and a prospective study had not been undertaken (Yeo 1990).
ACE inhibitor cough is probably related to inhibition of the metabolism of kinins which
facilitate the cough reflex at sensory fibres in the airways (Choudry et al 1989b). The sensory
nerves involved are thought to be C-fibres because patients with ACE inhibitor cough have an
enhanced response to inhaled capsaicin, a potent stimulant of sensory C-fibres (Fuller 1987,
McEwan 1989). Capsaicin inhalation causes cough in a dose-dependent manner (Morice
1992, Foster 1991). It is unknown whether all patients treated with ACE inhibitors have a
change in the cough reflex or only those who go on to develop cough. It is also unknown if
those who develop cough have a different cough reflex initially, prior to treatment.
In this next section I describe a prospective controlled study of the effect of the ACE inhibitor
enalapril on symptoms of cough and the cough reflex as determined by response to capsaicin.
5.2 AIMS
The aims of this study were:
1. To determine the natural history of the development and persistence of ACE inhibitor
cough.
2. To quantitate serially the development of cough by the use of questionnaires and visual
analogue scales.
3. To record changes in the response to inhaled capsaicin over time in those with ACE
inhibitor cough, by comparison with patients treated with enalapril but with no cough, and
control patients on alternative antihypertensive treatment.
5.3 METHODS
5.3.1 Subjects
This was a prospective controlled study over twelve months of symptoms and the cough reflex
in patients who commenced a new drug for hypertension. Twenty-one patients (11 women, 10
men; mean age 62 years) starting enalapril, and 12 controls (5 women, 7 men; mean age 56
years) starting any other antihypertensive drug were recruited from the Sheffield Hypertension
Clinic. Treatment allocation was by the doctor in the clinic who also invited them to
participate in the study. The treatment chosen was not randomised however the assessment of
cough symptoms and sensitivity to inhaled capsaicin were by an independent observer blinded
to the nature of treatment taken.
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The criteria for diagnosis of ACE inhibitor cough during the study were (a) a new onset of
cough during ACE inhibitor treatment (b) persistence of the cough for longer than three weeks
and (c) no other identifiable cause. These clinical criteria have a positive predictive value of
95% for ACE inhibitor cough (Yco 1991). An additional criterion used for this study was
resolution of the cough after stopping enalapril treatment. Patients gave written informed
consent to the study which was approved by the hospital ethics committee.
5.3.2 Study design
Patients attended on six occasions; at recruitment (baseline) and 1, 3, 6, 9 & 12 months after
starting treatment. At each visit subjective cough was measured by a self-administered
questionnaire (Appendix 1.2; Fletcher et al 1990) and visual analogue scales; VAS (Chapter
2; Appendix 4); cough reflex testing was performed as described below; and FEVy FVC and
PEFR were recorded.
5.3.3 Measurements
Capsaicin challenge was performed by single inhalations via a De Vilbiss no 40 nebuliser of
four doses of capsaicin. 0.05, 0.2, 0.8, and 3.2 nmol in random order with three minute
intervals between doses. These doses have been previously shown to lie on the steeper part of
the dose-response curve for cough response to capsaicin (Foster et al 1991). The number of
coughs occurring during one minute after each dose was recorded.
5.3.4 Measurements ofsubjective cough.
The severity of cough was measured by a validated self-administered questionnaire grading
cough as not at all [0], a little [1], moderately [2], quite a bit [3] or extremely [4] (Fletcher et
al 1990). Severity and frequency of cough were measured by two validated 10 cm visual
analogue scales (Chapter 2; Fletcher et al 1990).
The primary endpoints were (1) the development of persistent cough during treatment, and (2)
comparison of changes in cough symptoms and capsaicin response at one month in three
groups of patients; (a) Those who developed ACE inhibitor cough, (b) those on enalapril who
did not develop cough, and (c) controls on alternative antihvpertensive therapy.
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5.3.5 Statistical analysis
Questionnaire and VAS scores for cough were analysed by Kruskal-Wallis non-parametric
ANOVA. This provides an analysis of variance for the three groups combined, and also
pairwise comparisons between groups with appropriate corrections for ties and multiple
comparisons (Siegel & Castellan 1988). Changes from baseline in response to capsaicin for
all groups combined were examined by ANOVA. Absolute capsaicin dose-response curves
were examined by analysis of variance appropriate to parallel line bioassay, giving estimates
of relative potency with 95% confidence intervals (Armitage & Berry 1987). In each analysis
the slopes (or common slope) were significant, and did not deviate from linearity or
parallelism.
5.4 RESULTS
The baseline characteristics for 21 patients starting enalapril and for 13 controls are shown in
Table 5.1. The groups were comparable with respect to age, sex, smoking habit, severity of
hypertension, and other concomitant antihypertensive drugs.
Table 5.1 Baseline characteristics (SD) for thirty-three patients at recruitment.
Baseline characteristic Enalapril (n=21) Controls(n=I2)
Age (years) 62(14) 56(15)
Sex 10M: 1 IF 7M:5F
Body mass index 27(4) 26(5)
Cigarette smoking (%)
- current 24% 17%
- ex-smoker 29% 33%
- non-smoker 48% 50%
Respiratory disease 2 (10%) 3 (25%)
Blood pressure (mmHg)
- svstolic 184 (24) 184 (25)
- diastolic 99 (13) 105 (19)
Number of anti¬
hypertensive drugs (before study) 2.3 (0.9) 1.9(0.8)
P-blocker 13 (62%) 7 (58%)
Diuretic 14 (67%) 6 (50%)
Calcium antagonist 2 (10%) 5 (42%)
Asp inn or NSAID 8 (38%) 4 (33%)
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5.4.1 Development ofACE inhibitor cough
Eight of 21 patients (38%, 95%CI 16 - 60%) who started on enalapril fulfilled the criteria for
ACE inhibitor cough (Table 5.2), while 13 patients did not subsequently develop cough when
followed for one year. The mean time to the onset of cough in the eight patients was 2.4 weeks
(range 1-6 weeks). This was based on recall of the onset of cough by patients at one month, or
at three months if the cough took longer than 4 weeks to develop. In the six patients who
stopped enalapril early due to cough it subsided completely after withdrawal of the drug. In
most the cough occurred both day and night, usually in bouts. In one case it caused vomiting
with the cough. Two patients of those taking other anti-hypertensive medication withdrew
early from the study because of treatment changes. At the end of the 12 months of observation
all but two of the enalapril-cough patients had withdrawn from the study. By contrast 10 of 13
patients in the group on enalapril who did not cough, and 10 of 12 patients in the control
group completed the study.
Table 5.2 Baseline characteristics and time to the onset of cough in the eight patients treated
with enalapril who developed ACE inhibitor cough.









1 57 F None NSAID no 2
2 73 F None no no 6
o 46 M Ex-smoker no no 2
4 72 F None Aspirin no 2
5 30 M Smoker no no 2
6 61 F Smoker Aspirin no 2
7 32 F None no no 2
8 75 F Ex-smoker Aspirin no 1
5.4.2 Subjective assessment ofcough
Changes in cough questionnaire score at one month were significantly different for patients
who developed enalapril-induced cough (median change +2), those on enalapril with no cough
(0), and controls (0; KW 12.9, p<0.01). In absolute terms these changes were the equivalent
of patients who had reported no cough at all coughing moderately at one month. Similar
changes were observed for cough severity measured by VAS in patients who developed
enalapril-induced cough (median +39 mm), those on enalapril with no cough (+3 mm), and
controls (+5 mm; KW 6.64, p<0.05). Changes for cough frequency by VAS showed the same
trend but did not achieve statistical significance (+29, 0, +1 mm respectively; KW 3.87,
p=NS; table 5.3).
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Table 5.3 Changes in cough at one month measured by self-administered questionnaire and
visual analogue scales, and by the response to inhaled capsaicin in 33 patients starting
enalapril or an alternative drug for hypertension.
Change at 1 Enalapril cough Enalapril no cough Controls(n=12) P*
month (n=8) (n=13)
Cough score by +2 0 0 0.01
questionnaire
Cough severity +39 +3 +5 0.05
VAS (mm)
Cough +29 0 + 1 ns
frequency VAS
(mm)
Capsaicin 4.7 0.9 0.5 0.0005
potency (ratio)
[95% CI1 [1.2- 18.51 [0.4-2.11 [0.3-0.91
*
p values cited are for the appropriate analysis of variance for the three groups combined.
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5.4.3. Capsaicin challenge
The sensitivity to inhaled capsaicin at baseline did not differ between groups (Figure 5.1), but
at one month a significant increase in capsaicin potency from baseline was observed for
patients with enalapril cough (Figure 5.1, 5.2; relative potency 4.7, 95% CI 1.2-18.5,
p<0.025). No significant change from baseline was observed for the enalapril non-cough
group (relative potency at one month 0.9, 95% CI 0.4 - 2.1), but a small and significant
decrease in capsaicin potency was seen for the control group (relative potency 0.5, 95% CI
0.3 - 0.9; Figures 5.3,5.4).
5.4.4 Relation between subjective cough measures and capsaicin response
There was a significant correlation between increased VAS scores measuring cough frequency
and severity at one month, and more severe cough by questionnaire (rs = 0.43, p<0.02, and rs
= 0.37, p<0.05 respectively; Figures 5.5a and 5.5b). Similarly more severe cough scores by
questionnaire and by VAS were reflected by increases in the capsaicin response at one month
(Figure 5.5c and 5.5d). For this purpose the capsaicin response was defined as the total cough
response - the sum of the coughs obtained for all doses of inhaled capsaicin (Foster et al
1991).
5.4.5 Effect of time on capsaicin-response in enalapril-treatedpatients without cough.
This effect was examined by using the data at baseline, 1, 6 and 12 months for the ten patients
in the enalapril group who did not experience cough and were able to complete the study.
ANOVA for three factors: time, patients, and doses of capsaicin revealed that only a small
proportion of the total variance observed (1.6%) was due to time (F=1.52, p=0.21). The
estimated means for the cough response to capsaicin by ANOVA for patients on enalapril, but
with no spontaneous cough, were 2.4, 2.1, 2.2 and 1.6 coughs min"' for baseline, 1, 6 and 12
months respectively. This trend towards a slightly diminished response with time was similar
to that seen in control patients.
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Capsaicin dose (nmol)
Figure 5.1 Dose-response curves for 33 patients (enalapril-induced cough, n= 8, ■,
enalapril and no cough n=13, □, and control group, n=12, •) before treatment (solid
line) and 8 patients with enalapril-induced cough, ■ (broken line) after 1 month of
treatment. Mean (±se)
Capsaicin dose (nmol)
Figure 5.2 Dose-response curves for 8 patients,", before treatment (solid line) and
after 1 month of treatment when they had developed cough (broken line) with
enalapril. Mean (±se)
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Figure 5.3 Dose-response curves for 12 control patients before treatment (solid
line) and after 1 month of antihypertensive drug treatment (broken line) Mean (±se)
0.20 0.80
Capsaicin dose (nmol)
Figure 5.4 Dose-response curves for 13 patients,□, before treatment (solid line) and


































A cough questionnaire scores
Figure 5.5 The changes from baseline in VAS scores (cough frequency and severity),
the changes in cough score by questionnaires and in response to inhaled capsaicin
displayed as correlations between these measurements.




Eight of 21 patients starting enalapril (38%) developed ACE inhibitor cough as defined by
pre-set clinical criteria know to have a positive predictive value of 95% (Yeo 1991). Six of
these patients could not complete a full year of observation because of the severity of the
cough. By one month these eight patients recorded significantly increased scores for cough by
questionnaire and by visual analogue scales when compared to patients who did not cough
with enalapril, and patients starting other antihypertensive treatment (Table 5.2).
In this study patients with persistent cough had normal sensitivity to inhaled capsaicin
initially. By one month the cough sensitivity had increased five-fold. This magnitude of
increase in potency is identical to the five-fold difference in relative potency observed between
patients with ACE inhibitor cough and control subjects in a previous study (Yeo et al 1991).
By contrast capsaicin sensitivity in patients with no cough and in controls was slightly
reduced, with the majority of the reduction occurring between the first and second
measurement.
In the study by McEwan et al [1989] three of twenty patients treated with enalapril and
ramipril for one week developed cough, and this was accompanied by an increase in capsaicin
sensitivity to lie beyond the 95% confidence interval for the whole group. However the
changes in capsaicin sensitivity were convincing only for enalapril, and the shift was not
significant because only three patients developed cough (McEwan et al 1989). The present
study demonstrates a substantial and statistically significant shift in capsaicin sensitivity in
those who developed cough. The small non-significant reduction in sensitivity in the group
taking enalapril who did not develop cough suggests that ACE inhibitor treatment increases
the capsaicin dose-response only in those who develop spontaneous cough.
The observations in those who did not cough and the control group are new findings as
previously there was little information on changes in capsaicin sensitivity over time within
patients. There has been no comparative data from other research for capsaicin sensitivity in
patients who do not experience spontaneous cough while taking an ACE inhibitor, or in
control patients not on ACE inhibitors. The responses to inhaled capsaicin were reproducible
within patients accounting for only a very small part of the total variance of between 1.5 and
4.2% in enalapril treated patients with no cough, and control patients. When significant
differences did occur in the control groups it tended to be a small decrease in potency of
capsaicin with time, and this was most pronounced between the first and second
measurements.
When the cough measurements were examined there were significant associations between
cough responses to capsaicin and measurements of severity and frequency of cough by visual
analogue scales and by questionnaire. This supports the notion that the abnormality
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underlying ACE inhibitor cough is an increase in C-fibre mediated sensitivity of the cough
reflex (Fuller & Choudry 1987, McEwan et al 1989).
The association between cough measured by questionnaire and capsaicin sensitivity (rs=0.49,
p<0.01) was somewhat weaker than that for visual analogue scales for cough severity and
capsaicin sensitivity (rs=0.65, p<0.001) suggesting that visual analogue scales may be more
sensitive than the questionnaire for measuring cough severity.
The incidence of cough in this study is higher than is expected from larger studies (Yeo 1990).
In an open uncontrolled prospective study Ravid et al found 18.6% of patients developed
cough, beginning after an unusually long time, a mean 24.7 weeks of treatment. They found
that the cough disappeared quite rapidly when treatment was stopped in about 2-7 days (Ravid
1994). Possible reasons for the higher incidence found in my study include chance or even the
introduction of bias. The study was open and non-randomised. Although the assessor was
blinded to the treatment the patient was aware ofwhat they were taking and that we were
examining side-effects of drugs with a particular emphasis on headache and cough. An
improved design would include double-blinding as regards the nature of the medication and
less emphasis on cough in the questionnaire. Whatever these biases might be, they would not
be expected to explain the highly significant findings of changes in cough sensitivity.
In summary:
•Eight of twenty-one patients starting enalapril developed spontaneous cough during one year.
•The time to onset of cough in these patients was 2.4 weeks (range 1 - 6 weeks)
•These patients had significantly increased scores for subjective cough by questionnaires and
visual analogue scales by one month.
•The sensitivity to capsaicin was increased by a factor of five by one month in those who
developed cough.
•By contrast patients who were started on enalapril but did not develop cough did not shift
their sensitivity to capsaicin significantly over a year of observation.
•Control patients on other treatments had a small reduction in capsaicin sensitivity which
occurred mostly between the first and second measurement.
•ACE inhibitor cough appears associated with a five-fold increase in sensitivity to inhaled
capsaicin which is present by one month after treatment is started, and these changes in
capsaicin sensitivity are significantly associated with changes in subjective cough scores.
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CHAPTER 6
RESOLUTION OF ACE INHIBITOR COUGH:
CHANGES IN SUBJECTIVE COUGH,
AND RESPONSES TO
INHALED CAPSAICIN, INTRADERMAL BRADYKININ AND SUBSTANCE-P.
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6.1 INTRODUCTION
About 25% of patients with cough due to ACE inhibitors have to stop treatment (Yeo 1990,
Yeo 1991a) and in the remainder continuing with treatment the cough is moderate to severe,
disturbs sleep, and a nuisance to others (Yeo 1991a). Although much is known about the
epidemiology of the cough its mechanism remains uncertain. As discussed in the previous
chapter it is thought that kinins such as bradykinin or substance P, normally metabolised by
the kininase II action of angiotensin-converting enzyme (Choudry 1989), may act on sensory
nerves to facilitate the cough reflex and cause spontaneous coughing. The dose response to
capsaicin is shifted to the left in those with ACE inhibitor cough (Chapter 5, Fuller 1987,
McEwan 1989). In the preceding chapter I found that most of the change occurred within one
month. ACE inhibitor cough is said to disappear rapidly, within one week of stopping
treatment (Coulter 1987, Hume 1989, Berkin 1989) but the time-course of resolution of cough
has not been examined in detail. This knowledge may be important when designing trials
examining the effects of ACE inhibitors or other drugs on cough, and one aim of this study
was to examine formally the time-course of resolution of ACE inhibitor cough.
The wheal response to intradermal bradykinin is potentiated by ACE inhibitor treatment
(Ferner 1987). This reflects ACE or kininase II activity in the skin and thus provides a
surrogate measure of tissue ACE activity. Substance-P is also metabolised in part by ACE
(Yokosawa 1985), and changes in perineuronal substance-P have been proposed as having a
role in ACE inhibitor cough (Thysell 1988, Morice 1987). I was interested to study responses
to intradermal bradykinin and substance-P relating these to symptoms of cough and changes in
the cough reflex. The association or dissociation of these measures of response to ACE
inhibition might cast light on the mediators ofACE inhibitor cough.
6.2 AIMS
The aims of this study were:
1. To examine the time-course of resolution of ACE inhibitor cough.
2. To examine the relations between changes in subjective cough, changes in the cough reflex




Patients taking enalapril who had ACE inhibitor cough were recruited from the Sheffield
Hypertension Clinic, using as the criteria for diagnosis (a) a new onset of cough during ACE
inhibitor treatment (b) persistence of the cough for longer than three weeks and (c) no other
identifiable cause. These clinical criteria have a positive predictive value of 95% for ACE
inhibitor cough (Yeo 1991). Patients gave written informed consent to the study which was
approved by the hospital ethics committee. Two of the subjects from the study in chapter 5
were recruited into this study.
6.3.2 Study design
This was a prospective observational study over four weeks of symptoms, cough reflex, and
skin responses to bradykinin and substance-P in patients with ACE inhibitor cough who
stopped the ACE inhibitor. Patients attended on five occasions; at recruitment (day 0) and
then 3, 7, 14 and 28 days after stopping the ACE inhibitor. At each visit subjective cough was
measured by a self-administered questionnaire and visual analogue scales (VAS; chapter 2);
cough reflex testing and skin testing were performed as described in chapter 2; and FEVj,
FVC and PEFR were recorded.
6.3.3 Measurements
Capsaicin cough challenge was performed as described in Chapter 2. The number of coughs
occurring during one minute after each dose was recorded.
Intradermal bradykinin and substance P tests were performed at each visit as described in
chapter 2. These intradermal tests were performed in 6 subjects but completed in only 5
because one developed a generalised macular rash at day 3.
Subjective cough. Severity of cough was measured by a validated self-administered
questionnaire described in chapter 2. The severity of these symptoms was graded as not at all
(0), a little (1), moderately (2), quite a bit (3) or extremely (4).
A diary relating to the nature of the cough was completed by the patient each day (Appendix
3). This consisted of six questions concerning nocturnal severity, frequency, da\time severity,




The scores from the self-administered questionnaire and visual analogue scales were analysed
by the non-parametric Friedman's two-way analysis of variance. The capsaicin dose-response
curves were analysed using a method for parallel line bioassay. The dose-responses for the
wheal areas to bradykinin and substance-P were significantly non-parallel, and these variables
were analysed by repeated measures ANOVA. Changes in FEVj, FVC and PEFR were also
examined by ANOVA. Multiple regression analysis was used to explore (i) the relations
between changes in subjective measures of cough and the cough response to inhaled capsaicin;
and (ii) the relations between four separate measures of cough (capsaicin response,
questionnaire-severity, VAS-ffequency, VAS-severity) and the changes in wheal areas to
substance-P and bradykinin. For those variables measured as dose-response curves the value
used for this analysis was the mean for all doses at each time point. This single summary
measure which represent the dose-response curve at each time point was regressed against
single measures for VAS and questionnaire at each time point. Multiple regression with
stepwise subtraction of non-significant predictors was performed with each of the four
measures of cough regressed separately against the responses to substance-P and bradykinin,




The baseline characteristics of the eight patients (7 women) are shown in Table 6.1. All had
been taking enalapril at doses between 2.5 and 40 mg daily for a median period of 8 months
(range 1.5-24 months), and had developed a dry cough which required discontinuation of the
drug. Five patients were non-smokers and three continued to smoke between 10 and 30 per
day (Table 6.1).
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1 50 F 29.5 116/90 2.5 1.5 Never
2 29 F 40.2 146/86 5 3 10 cigs/day
3 71 F 37.3 170/98 5 24 Ex-smoker
4 75 F 21.9 180/70 2.5 1.5 Ex-smoker
5 73 F 29.5 218/100 20 4 Never
6 60 F 30.7 180/82 5 12 10 cigs/day
7 54 F 25.3 154/100 40 24 30 cigs/day
8 65 M 28.6 140/72 20 24 Ex-smoker
6.4.2 Subjective symptoms ofcough
All patients recorded a subjective improvement in cough as measured by the questionnaire
scores for severity and night time waking, and by visual analogue scales for severity and
frequency of cough (Table 6.2). The median questionnaire score for severity fell from 3
("quite a bit") to 0.7 ("not at all" to "a little") over the 28 days (p<0.01). The change in
severity score was significant by day 7, with further reductions by day 14 and 28 (Table 6.2).
Night time cough was significantly reduced from 2.2 ("moderately") to 0.7 by 14 days
(p<0.05) with a further decrease to 0.1 ("not at all") by 28 days (p<0.01, Table 7.2). The
frequency of cough measured by visual analogue scale fell from 6.2 cm to 4.8 cm by day 3
with further declines to 0.8 cm (p<0.01, Table 6.2) at day 28. The severity of cough by visual
analogue scale was significantly reduced from its starting value of 6.5, to 2.9 cm by day 7
(p<0.05), 1.6 cm by day 14 (p<0.05) and 0.8 cm at day 28 (p<0.01; Table 6.2).
The diary showed resolution in night time cough in seven subjects after 4 weeks, but the cough
was still present in three subjects (subjects 5,6, and 7) to some degree by the end of the study.
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Table 6.2. Subjective and objective measures of cough: estimated median scores by self-
administered questionnaire (SAQ) for severity of cough and night time cough, visual analogue
scales (VAS) for severity and frequency of cough, and relative potency estimates for
capsaicin, with 95% CI. The potency at day 0 is set at 1.0 and potency estimates for capsaicin
at subsequent time points are relative to this value.
SAQ V.A.S. Capsaicin
score (cm) relative potency
Date Severity Nighttime Severity U Frequency (95% CI)
^ cough H
day 0 3.0 2.2 6.5 6.2 1.00
day 3 2.5 2.0 4.8 *OO 0.34 (0.09 - 1.03)
day 7 1.8* 1.0 2.9* 3.1* 0.46 (0.16 - 1.35)
day 14 1.5* 0.7* 1.6* 1 4** 0.25* (0.07 -0.87)
dav 28 0.7** 0.1** 0.8** 0.2** 0.18** (0.06 -0.67)
P <0.0005 for trend from day 0 to day 28 * P < 0.05, ** P < 0.01 versus day 0
6.4.3 Respiratoryfunction
There were no changes in FEVj, FVC and PEFR over the period of the study.
6.4.4 Capsaicin challenge
The sensitivity to inhaled capsaicin fell over the 28 days of study after stopping enalapril. The
potency of capsaicin relative to day 0 was significantly reduced to 0.25 (95% CI 0.07-0.87)
by day 14, and there was a further reduction in relative potency to 0.20 (95% CI 0.06-0.67)
by 28 days (Table 6.2). There was therefore a significant shift to the right in the dose response
curve to inhaled capsaicin after patients stopped the ACE inhibitor (Figure 6.1).
6.4.5 Wheal area to intradermal bradykinin and substance-P
After stopping enalapril there was a highly significant reduction in wheal area produced by
intradermal bradykinin, with the majority of the effect seen by day 3 (Table 6.3, Figure 6.2).
The wheal area to intradermal substance-P also declined with time after stopping enalapril,
but significant changes were not observed until 14 days, with a further reduction by 28 days
(Table 6.3, Figure 6.2).
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Table 6.3 Mean wheal area (mm^) 15 minutes after a 0.1 ml intradermal injection of
bradykinin and substance-P in five patients from day 0 to day 28 after stopping ACE inhibitor
treatment..
Date
Bradykinin dose (pg/ml) H
0.1 1.0 10 100
Substance-P (pg/ml) *[
0.001 0.01 0.1 1.0
day 0 99 137 227 343 73 83 126 218
day 3* 68 86 118 201 60 87 127 199
day 7* 68 96 130 163 52 80 105 180
day 14*f 61 82 104 160 49 68 103 176
day 28 52 82 114 145 43 64 89 139
P<0.0005 for trend day 0 to day 28.


















0.20 (95% CI 0.06-0.67)
DAY 28
0.05 0.2 0.8 3.2
Capsaicin dose (nmol)
Figure 6.1 Dose-response to capsaicin in eight patients at day 0 and day 28 after
stopping ACE inhibitor treatment. The shift to the right in dose-response represents a
reduction in relative potency of capsaicin at 28 days of 0.2 compared to day 0,
p<0.005.
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Figure 6.2. Relation between offset of ACE inhibitor cough as assessed by visual analogue
scales for cough severity and frequency (VAS, open half circles), self administered
questionnaires for severity of cough (SAQ, 0) and capsaicin challenge ($) with the
intradermal responses to bradykinin (A) and substance-P (V). The changes are represented as
a percentage reduction between day 0 and day 28 in the five patients who had all variables
recorded.
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6.4.6 Relation between subjective cough and capsaicin response
The rates of decline for the subjective and objective measures of cough, and for responses to
intradermal bradykinin and substance-P, are shown in figure 2 for the five patients who had
all the tests performed. The time-course of changes in questionnaire cough severity, VAS
scores for severity and frequency of cough, and responses to inhaled capsaicin were broadly
similar. Multiple regression analysis showed significant associations of the response to
inhaled capsaicin with the VAS score for severity of cough (regression coefficient 0.13,
p=0.005) and the VAS score for frequency of cough (regression coefficient 0.11, p=0.011).
Capsaicin response was not related significantly to the severity of cough measured by self-
administered questionnaire.
6.4.7 Relation between measures ofcough and responses to intradermal bradykinin and
substance-P
The changes in wheal area to bradykinin appeared to occur more rapidly after stopping
enalapril than did changes in measures of cough, while those for substance-P appeared to
diverge at day 14 (Figure 6.2). Multiple regression analysis showed a significant association
between bradykinin response and VAS scores for frequency of cough (regression coefficient
0.021, p<0.04) and severity of cough (regression coefficient 0.022, p<0.05), but not with
cough by questionnaire or the capsaicin response. The response to substance-P did not relate
significantly to any of the measures of cough. When the response to substance-P was removed
from the regression equation there was no longer a significant relation between bradykinin
response and measures of cough. However in all analyses bradykinin explained more of the
variance in cough responses than did substance-P. For example bradykinin explained 23% of
the variability in VAS scores for frequency of cough, 22% for VAS scores for severity of
cough, 8% for questionnaire responses for severity of cough, and 11% for the response to
capsaicin, after removing variance related to time-course and between-patients. The
corresponding figures for substance-P were 0.0%, 0.1%, 2.6% and 0.0%.
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6.5 DISCUSSION
Before discussing the findings, possible limitations of this study should be mentioned. The
study was an open observational study with no control group, and it is therefore not possible
to exclude some element of error due to patient or investigator bias. As there was no control
group the study relies on the responses measured being relatively reproducible and stable over
time. I believe these factors have not greatly influenced the results presented for three reasons.
Firstly there is internal consistency across all patients within the study; secondly the changes
observed for the responses are much greater than the within-subject coefficient of variation for
these responses when performed under controlled conditions; and lastly these findings are
consistent with the findings of a double-blind study as will be discussed below.
ACE inhibitor cough is thought to resolve rapidly, within one week of stopping treatment
(Coulter 1987, Hume 1989, Berkin 1989), but these impressions predate quantitative methods
of assessing ACE inhibitor cough (Yeo 1991a, Fletcher 1990, Yeo 1991b, Yeo 1995). In this
studj' cough related to enalapril resolved after the ACE inhibitor was stopped, with reductions
in measures of the severity and frequency of cough and night-time cough, but resolution took
longer than one week. There was a significant improvement 14 days after stopping enalapril,
but complete disappearance of the cough during the daytime was observed only after 28 days.
This is in agreement with a recent controlled study in which patients with ACE inhibitor cough
were challenged, de-challenged and re-challenged with lisinopril (Lacourciere 1994). The
median time to complete resolution of the cough caused by lisinopril was 26 days (Lacourciere
1994). The capsaicin cough sensiti\ity in those with chronic cough of various causes was
examined by O'Connell et al (1990). In a small group which included four subjects taking
ACE inhibitors successful identification and treatment of the cause of the cough was
associated with not only resolution in the symptoms but a decrease in the cough sensitivity to
inhaled capsaicin. Interestingly in those who continued to have symptoms with no cause
identified the cough response to capsaicin did not change.
There was a highly significant association between cough responses to capsaicin and
measurements of severity and frequency of cough by visual analogue scales. This supports
suggestions that the abnormality underlying ACE inhibitor cough is an increase in C-fibre
mediated sensitivity of the cough reflex (Fuller 1987, McEwan 1989, Yeo 1995). There was
no significant association between cough measured by questionnaire and capsaicin sensitivity,
suggesting that the visual analogue scales may be more sensitive than the questionnaire for
measuring cough. This finding was also seen in the previous chapter where the visual
analogue scores showed significant association with changes in cough sensitivity to capsaicin
but the questionnaire only showed an association when cough was rated as severe.
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While the significant increase in capsaicin sensitivity in patients with ACE inhibitor cough is
now well established (Fuller 1987, Yeo 1995, chapter 5), there is little information on changes
in capsaicin sensitivity over time within patients. In one study (McEwan 1989) three of twenty
patients treated with enalapril and ramipril for one week developed cough accompanied by an
increase in capsaicin sensitivity to lie beyond the 95% confidence interval for the whole group.
However the change in capsaicin sensitivity was convincing only for enalapril, and the shift
was not significant because only three patients developed cough (McEwan 1989). With
hindsight the treatment and washout periods of one week were probably too short (McEwan
1989).
My study shows a substantial and highly significant reduction in sensitivity of the cough
reflex to capsaicin after stopping enalapril. The relative potency of capsaicin was reduced by
one week, fell significantly to 0.25 of the starting value by 14 days, and declined further to
0.20 by 28 days (Table 6.2, Figure 6.2). The five-fold fall in potency of capsaicin over 28
days after stopping enalapril in the present study is identical to the five-fold difference in
relative potency observed between patients with ACE inhibitor cough and control subjects
(Yeo 1995), and suggests that the cough reflex had returned to normal four weeks after
stopping treatment. In chapter 5 the five-fold increase in capsaicin sensitivity found occurred
during the first month of treatment. There were no other assessments at other time-points
during this period and the initial rate of change could not determined.
Recent evidence from a study comparing the specific angiotensin II antagonist losartan to
lisinopril in patients with ACE inhibitor cough (Lacourciere 1994) indicates that kinins are
likely to be involved in the cause of ACE inhibitor cough (Lacourciere 1994, Coulter 1987,
Yokosawa 1985, Thvsell 1988, Morice 1987). The wheal area in response to intradermal
bradykinin and substance-P showed progressive and highly significant declines after stopping
enalapril. For bradykinin this change occurred rapidly, with 80% of the reduction occurring
by day 3 (Table 6.3, Figure 6.2), and this appeared to be dissociated from changes in cough
over the first 14 days. The wheal response to substance-P paralleled changes in cough more
closely (Figure 6.2), but appeared to diverge at day 14. Multiple regression analysis showed a
weak but significant association between bradykinin response and visual analogue scale
measurements but not with questionnaire responses or capsaicin sensitivity. Bradykinin
accounted for 22-23% of the variance in VAS cough not explained by variability related to the
time-course or patients. There was no association between the wheal responses to substance-P
and measures of cough. These findings give some support to the hypothesis (Coulter 1987,
Berkin 1989) that bradykinin may be a mediator of ACE inhibitor cough, but provide no
positive support for substance-P as a likely mediator. However intradermal responses to these
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peptides may not reflect events in the respiratory tract, and there may be type II error as the
sample size was small.
I conclude that cough caused by enalapril improves markedly by 14 days but takes up to 28
days to resolve completely after stopping the ACE inhibitor, and the same is true for lisinopril
(Lacourciere 1994). The offset of cough could be more rapid with ACE inhibitors that have a
shorter half-life, but the offset for enalapril and lisinopril is far longer than would be predicted
from their plasma half-lives or duration ofaction (Mclnnes 1993). One immediate practical
implication is that studies examining ACE inhibitor cough are likely to require washout
periods of at least 28 days. ACE inhibitor cough is associated with increased sensitivity to
inhaled capsaicin which is reversed over 28 days after treatment is stopped.
Changes in capsaicin sensitivity parallel those in subjective cough supporting suggestions that
ACE inhibitor cough is caused by facilitation of the C-fibre mediated cough reflex. Change in
response to intradermal bradykinin was a better predictor of cough responses than that for
substance-P, and accounted for about a quarter of unexplained variability in the changes in
visual analogue scales for cough during the resolution of ACE inhibitor cough.
In summary:
• cough caused by enalapril improves markedly by 14 days but may takes up to 28 days or
more to resolve completely after stopping the ACE inhibitor.
• changes in capsaicin sensitivity parallel those in subjective cough.
• change in response to intradermal bradykinin was a better predictor of cough responses





RESPONSES TO INHALED BRADYKININ
IN HEALTHY SUBJECTS
7.1 INTRODUCTION
Bradykinin has been implicated in the pathogenesis of cough due to ACE inhibitor treatment
and increased serum levels have been recorded in those with this adverse effect (Puolijoki
1992). Bradykinin stimulates the C-fibres via specific receptors (Kaufman et al 1980,
Simasson et al 1973) probably through the release of sensory tachykinins such as substance P,
neurokinin A, and calcitonin gene-related peptide (Polosa 1992). Subsequent activation of
cholinergic pathways can lead to bronchoconstriction in laboratory animals. Bradykinin has a
bronchoconstrictor response in those with asthma but not in healthy individuals (Simonsson
1973, Fuller 1987). Cough, unrelated to any change in airways calibre, was observed to
varying extent in these and other studies (Dixon 1987, Choudry 1989, Ichinose 1992).
However these studies were not designed to specifically look for cough and did not give much
information on its nature or severity.
Only 20% of those taking ACE inhibitors develop cough, and this led to the hypothesis that
there may be a genetic component in its development (Yeo et al 1991). The ACE gene
polymorphism was a possible candidate in that those subjects of genotype II, ie low serum
ACE activity, may have a lower threshold to bradykinin and its potential effects. I have tested
this hypothesis by administering bradykinin to healthy subjects grouped according to ACE
genotype.
7.2 AIMS
1. To examine the effects of bradykinin on the cough response and airways function in
healthy subjects.
2. To examine the relation of the ACE genotype to these acute effects of bradykinin on the
cough response and airways function.
7.3 METHODS
7.3.1 Subjects
Twenty-seven healthy subjects (11 males and 16 females) ofmean age 28.4 years (range 20-
51), were selected to provide equal numbers of the three genotypes (n=9 for each of the
genotypes DD, ID and II). They gave written informed consent to the study which was
approved by the district ethics committee. Those with asthma, eczema, multiple allergies, a
previous reaction to bradykinin, a respiratory infection within the last 2 weeks and current
cigarette smokers were excluded from the study. Seven of the subjects had taken part in the
study in chapter 4.
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7.3.2 Study design.
Each subject was given six doses of bradykinin in the order described below following an
initial administration of 10% ethanol in saline in an open parallel group comparison of the
genotypes. Subjects attended in the afternoon having refrained from caffeine containing drinks
for 12 hours. Baseline readings of forced expiratory volume in one second (FEVj)were
recorded on arrival and five minutes later. Subjects then underwent seven cycles of test
substance inhalation from a compressed air nebuliser controlled by a breath activated
dosimeter (Mefar,Bovezzo,Italy). A noseclip was applied to ensure consistent mouth
breathing. During each cycle subjects took three separate breaths, each of the same dose,
from the nebuliser at one minute intervals, breathing room air between inhalations. At the end
of the cycle the FEV j was rechecked. After a further minute the cycle was repeated for a
different dose.
Bradykinin (Sigma,UK) in 10% ethanol in saline, was administered in the following doses:
0.125 mg/ml, 0.25 mg/ml, 0.5mg/ml, lmg/ml, 2mg/ml, 4mg/ml.
The order of administration of bradykinin was not randomised and followed the same order in
each subject. This was as follows: saline-> 3-» 4-» 5—» l-» 6—> 2; where l=lowest dose &
6=highest dose. This order was not known by the observer who was recording the cough.
If a reduction of 20% in FEV j was found the test was stopped and FEVj recorded at five
minute intervals until it returned to baseline.
7.3.3 Measurements
The cough response for each dose and the total cough response (TCR) for all doses were
recorded by an observer blinded to the nature and dose of the test substance and genotype of
the subject. Forced expiratory volume in 1 second was recorded by vitalograph. ACE
genotype was determined by polymerase chain reaction as described in chapter 2. Serum ACE
activity was measured by fluorimetric assay with units expressed as nmol of histidyl-leucine
produced per ml of sample per minute (Freidland 1976).
7.3.4 Statistical analysis
Baseline differences and changes in FEV[ were studied using one-w ay analysis of variance.
The mean change in FEVi, that is the mean of the change from baseline for each dose for each
subject, following administration of bradykinin, was calculated. Kruskal-Wallis tests were
used to examine the difference between the cough scores between the genotypes. The total
cough response was corrected for response to control. The relationships between cough
response, changes in FEV and serum ACE were examined by Spearman rank correlation.
Bradykinin produced a fall in FEV i of over 20% in one subject associated with symptomatic
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wheeze. A further subject developed symptomatic wheeze associated with a fall in FEV i of
18%. These two individuals did not receive all doses of bradykinin however their results are
included in subsequent analyses.
7.4 RESULTS
7.4.1 Comparability ofgroups
(Table 7.1). Subjects from the three genotypes were of similar age but differed as regards the
distribution of sexes with the ID group having fewer men. Average baseline FEV j as a
percentage of that predicted for height and sex was similar in the three groups. In 15 subjects
serum ACE was measured. There was a significant relation between ACE genotype and serum
ACE activity at baseline (table; p<0.03 between groups), with DD subjects having mean
serum ACE activity 65% higher than that of II subjects. The ACE genotype accounted for
38% of the between-subject variance in serum ACE activity at baseline.
7.4.2 Changes in respiratory function.
(Table 7.1, Figure 7.1) The mean change in FEVi, following administration of bradykinin,
was 1.3% (se 1.4) compared with the control (10% ethanol in saline) which was 0.5% (se
0.7) [difference 0.8%; 95% CI -2.3 to 3.9%, p=0.5 8], Those ofgenotype DD had a mean
change in FEV; (over all dose) following bradykinin of -2.5% compared with those of
genotype II in who it was 3.8% (Difference DD-II =-6.3%; 95%CI -15.0-2.4; p=0.05)
7.4.3 Cough response to bradykinin.
(Table 7.1, Figures 7.2, 7.3) Bradykinin caused a cough in 20 subjects (74%) compared to the
control (10% ethanol in saline) which caused cough in 4 subjects (15%; p<0.05). The
response to bradykinin decreased after the initial administration suggesting tachyphylaxis
(Figure 7.4). Thus a summary measure, the total cough response to all doses of bradykinin
was used (Figure 7.2). This was corrected for changes from control (saline). This showed no
significant difference between the genotypes (median number of coughs; DD = 6.0, ID = 4.0,
II = 10.0; p> 0.05). There were no significant differences between the genotypes for cough
after the first dose (Figure 7.3; median coughs/min: DD = 0.0, ID = 2.0, II = 2.0 ; p> 0.05).
Total cough response v Changes in FEV/
(Figure 7.5) The total cough response did not correlate with the mean change in FEVi
(rs=-0.20).
Serum ACE activity v cough response.
The total cough response did not correlate with initial ACE activity (rs= -0.21).
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Table 7.1. Baseline data, cough response and changes in respiratory function following
inhaled bradykinin for 27 healthy subjects according to ACE genotype
Genotype DD ID II
Age (years; mean; sd ) 25.9 (7.0) 32.2(10.8) 27.0(4.7)
FEV i (% predicted; mean; sd) 97.1 (16.3) 107.0(17.1) 105.3 (14.7)
ACE activity*
(nmol/ml/min; mean; sd)
23.7(8.0) 20.8 (5.1) 14.3 (4.7)
Subjects who coughed after bradykinin 6 6 7
No. of coughs following 0.5mg/ml
bradykinin (median; range)
0.0 (0-6) 2.0 (0-12) 2 (0-7)
Total no. of coughs
(median; range)
6.0 (0-27) 4.0(0-21) 10.0 (0-30)
Change in FEVj from baseline
(%; mean; se)
-2.5 (2.0) -0.1 (0.2) 3.8(3.6)






























Figure 7.1 The mean change in FEV i following inhaled bradykinin in 27 healthy









































Figure 7.2 The total number of coughs/min following all doses of inhaled bradykinin
in 27 healthy subjects grouped according to ACE genotype,


































Figure 7.3 The total number of coughs/min following the first dose of inhaled
bradykinin in 27 healthy subjects grouped according to ACE genotype, >=DD
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Order bradykinin dose administered
Figure 7.4 The cough response to inhaled bradykinin in 27 healthy subjects grouped
according to ACE genotype, in order that the doses were administered. ^DD

































Figure 7.5 The total number of coughs/min v the mean change in FEVi following
inhaled bradykinin in 27 healthy subjects grouped according to ACE genotype, «=DD
genotype, □ = II genotype and A =ID genotype.
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7.5 DISCUSSION
Bradykinin administered by inhalation caused a cough in 74% of subjects compared to a
control inhalation which caused cough in 15%. The changes in FEVi produced by bradykinin
were not significantly different to that of ethanol in saline. However, despite the exclusion of
asthmatic and atopic subjects there were significant falls in FEVj enough to cause clinical
bronchoconstriction in two subjects. In one of these subjects a family history of atopy was
subsequently found to be present. In view of the potential severity of bronchospasm following
inhaled bradykinin it would probably be advised that not only those with a personal history
but also those with a family history of atopy are excluded from further studies of healthy
volunteers. The cough response did not appear to correlate with changes in airways function.
The cough response did not differ between genotypes when examined either as initial response
or as total cough response. This may indicate that ACE is not as important for bradykinin
metabolism on the surfaces of the upper airways as other enzymes and thus differences in
activity of ACE become unimportant. When ACE inhibitor drugs lead to cough this develops
usually after 7-28 days of treatment and this acute model may not be suitable.
The design of the study was flawed by the use of the same order of administration of doses of
bradykinin. When the cough response was related to the order of administration of the drug,
(Figure 7.4), it appeared that tachyphylaxis occurred. The use of the same order of
administration for each subject may exacerbate this phenomenon when the group as a whole
are studied. Tachyphylaxis to bradykinin has been noted when bronchoconstrictor responses
were studied in asthmatic subjects (Polosa 1992a) possibly due to depletion of the sensory
neuropeptides. When Polosa et al examined mucociliary clearance following bradykinin in
healthy subjects they noted that a dry cough occurred in some subjects. Some subjects noted a
pharyngeal irritation which rapidly diminished during subsequent inhalations (Polosa 1992b).
An alternative explanation for the failure to show a dose-response might be that the doses
examined were on the plateau of the dose-response curve for cough. Bradykinin often caused
only one or two coughs and thus using direct observation it may not be possible to conduct
dose-response curves. The potential adverse effect of unexpected bronchoconstriction seen in
some healthy volunteers would probably limit the use of higher doses in future research.
In conclusion although bradykinin caused or stimulated cough in health}- subjects this does not
appear to be related to ACE genotype or to a reduction in FEV i.
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In summary:
• Bradykinin administered by inhalation causes cough in healthy subjects.
• Bradykinin can produce significant bronchoconstriction associated with wheeze in non-
asthmatic subjects.
• Cough in response to bradykinin does not appear to be related to ACE genotype.
• Cough in response to bradykinin does not appear to be related to changes in airways










The insertion/deletion (I/D) polymorphism of the angiotensin converting enzyme (ACE) gene
which consistently predicts differences in serum ACE activity has not been examined fully as
regards tissue ACE. Costerousse et al examined ACE bound to T lymphocytes (Costerousse
et al 1993), and reported that ACE genotype predicted lymphocytic ACE activity. The
lymphocytic ACE activity differed between genotype in the same way as serum ACE but the
relationship was not as strong (Costerousse et al 1993).
Bradykinin is a decapeptide involved in inflammatory reactions, and is metabolised by ACE.
When injected intradermally bradykinin causes a dose-dependent wheal and flare response
(Basran 1982), and this response is increased by treatment with ACE inhibitor drugs (Femer
et al 1990). In chapter 6 I was also able to demonstrate an increased response to bradykinin
with ACE inhibitors. Thus the wheal response to intradermal bradykinin provides a measure
of tissue ACE activity. In this chapter I examined the relationship between ACE genotype and
the dermal wheal response to bradykinin in healthy subjects to find out if the ACE genotype
might be related to tissue ACE activity.
8.2 AIMS
1. To examine the relationship between ACE genotype and tissue ACE activity using the
dermal wheal response to bradykinin as a measure of tissue ACE activity
8.3 METHODS
8.3.1 Subjects
One hundred and five healthy subjects (50 men and 55 women) were recruited by open
invitation and gave written informed consent to the protocol which was approved by the local
ethics committee. Subjects with asthma or eczema were excluded. The 105 subjects
comprised 30 subjects with DD genotype, 51 subjects with ID genotype, and 24 subjects with




Each subject was given four doses of bradvkinin and of histamine intradermally, with both
the investigator (M. Kraskiwicz) and subjects blinded to the genotype status. Histamine was
included as a "negative control" because its metabolism, unlike that of bradykinin, is not
influenced by ACE (kininase II) (Anderson 1990). Skin tests were performed as described in
chapter 2. Bradykinin and histamine were injected intradermally in doses of 0.001, 0.01, 0.1
and lpg.
8.3.3 Measurements
The wheal areas in response to intradermal bradykinin and histamine were measured at 15
minutes by drawing round the wheal in ink and transferring the image to graph paper using
adhesive cellophane tape then measured using digitised planimetry.
ACE genotype was determined by polymerase chain reaction as described in chapter 2.
8.3.4 Statistical analysis
The sample size was calculated according to Pearson-Hartley Power Charts (Maxwell 1990)
to have 80% power at a significance level of p<0.05 to detect a 50mm^ difference between the
groups in the response to bradykinin, using a standard deviation of 118 mm^ derived from
previous studies within our department. The bradykinin dose response curves were analysed
using a parallel line bioassay method (Armitage and Berry 1987) which estimates the relative
potency of bradykinin with 95% confidence intervals. The relative potency of bradykinin in
subjects of different ACE genotype is a measure of shift of the dose-response curve to the left
or right in relation to the ACE genotype.
8.4 RESULTS
8.4.1 Comparability ofgroups (Table 8.1). The subjects in the three genotypes were well
matched for age, body mass index and blood pressure. The groups differed as regards sex
distribution, with fewer female subjects in the ID group (37%) than in the DD and II groups
(57%). This is ignored in the analysis as the sex distributions were similar in the DD and II
groups, the comparison of prime importance.
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Table 8.1 Characteristics of subjects in relation to ACE genotype (mean ± sd).
DD ID II
number each group 30 51 24
age (years) 26 (7.4) 25(6.5) 25.8(6.8)
sex (m/f) 17/13 19/32 14/10
BMI 22 (2.3) 22 (3.1) 22 (2.7)
systolic BP (mmHg) 112 (10) 112 (10) 117 (11)
diastolic BP (mmHg) 72 (8) 71 (7) 71(7)
8.4.2 Dermal responses (Table 8.2, Figure 8.1) Intradermal injection of bradykinin
produced dose-dependent increases in wheal area, with dose-response curves which did not
deviate from linearity and parallelism (both p>0.05), and were highly significant (p<0.01,
Figure 3.1a). In the parallel-line analysis the potency of bradykinin in subjects of II
genotvpe relative to those ofDD genotype was 1.25, with a 95% confidence interval of 0.83
to 1.88. As the confidence interval bracketed unity the difference between II and DD groups
was not statistically significant. Intradermal injection of histamine also produced dose
dependent increases in wheal area which were linear, parallel and highly significant (Figure
3.1b). The potency of histamine in II subjects relative to DD subjects was 1.16 with a 95%
confidence interval 0.71 to 1.88. Thus the relative potencies of bradykinin, which is
metabolised by ACE, and histamine, which is not, were similar when comparing subjects of
genoPpe II to those of DD genotype.
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Table 8.2 Wheal areas (mm ) in response to intradermal bradykinin and histamine related to
ACE genotype (mean ± se).
Bradykinin dose DD ID II Potency
(us) (n=30) (n=51) (n=24) (II relative to DD)
0.001 41.6 (3.2) 39.0(1.7) 38.6 (2.3) 1.25
0.01 57.6(3.5) 57.9(2.4) 63.8 (3.7) 0.88-1.88 (95%CI)
0.1 78.6 (2.9) 81.4 (3.7) 84.7 (3.7)
1.0 107.7 (4.9) 107.8 (5.0) 107.1 (5.6)
Histamine dose DD ID II Potency
(h.g) (II relative to DD)
0.001 39.0 (2.2) 35.7(1.7) 39.2 (2.1) 1.16
0.01 53.7(3.5) 52.8 (2.4) 59.3 (5.1) 0.71-1.88 (95%CI)
0.1 83.4 (5.4) 76.5 (4.0) 81.8 (4.5)
1.0 134.0(7.4) 129.7 (6.1) 137.8 (10.7)
8.4.3 Total area ofwheal.
(Table 8.3) The total wheal area produced by bradykinin was calculated by summing the
individual responses for each subject. The total wheal area produced by bradykinin was 285.6
mm^ in DD subjects and 294.2 mm^ in II subjects (diffDD-II 8.6mm^; 95%CI -39.5 to 22.3
mm^). This difference was not statistically significant. For histamine the wheals were 310.0
mm^ in DD subjects and 318.1 mm^in II subjects (diffDD-II 8.2mm2; 95%CI -50.0 to 33.8
mm^).
Table 8.3. The total area of skin wheal produced from 4 doses of bradykinin and histamine
(mean ± se)
DD ID II DiffDD-II 95% CI
Bradvkinin 285.6 (11.7) 286.2 (10.7) 294.2 (12.0) -8.6 -39.5 to 22.3
(mm2)
















Figure 8.1 The wheal responses to intradermal bradykinin (fig 8.1a) and
histamine (fig 8.1b) in 105 subjects grouped according to ACE genotype. Figure




The relationship between ACE genotype and serum ACE has been observed consistently, with
subjects of genotype II having a low serum ACE activity. If this was mirrored by lower tissue
ACE activity they would be expected to have increased wheal responses to bradykinin.
Measuring tissue ACE activity in-vivo is difficult due to the close proximity of extra-cellular
and intra-vascular fluids and thus serum ACE. The dermal response to bradykinin is a
measure ofACE activity at the tissue level (Femer 1989, Fuller 1989).
In my study the potency ofbradykinin on wheal response did not differ significantly between
the three ACE genotypes. In using dermal response to bradykinin I adopted a different
approach to examine the relation between the ACE genotype and activity ofACE in tissue. It
has been shown that treatment with ACE inhibitors increases the dermal response to
bradykinin, indicating that the renin-angiotensin system has a readily measurable role within
the dermal tissues (Chapter 6). My results show no significant difference in the potency of
bradykinin in dermal wheal response between subjects of DD and II genotypes. There was a
trend for subjects of genotype II to have larger responses to bradykinin, but the study had
sufficient power to exclude a potency in II subjects greater than 1.88 relative to DD subjects.
Moreover the findings for intradermal histamine, whose effect is independent of ACE, were
similar to those for bradykinin with a trend towards a slightly higher potency in subjects of II
genotype. Thus the polymorphism in the ACE gene that is associated with a marked
difference in ACE activity in serum shows no relation to the activity of ACE in dermal
tissues.
While the polymorphism in the ACE gene is associated with differences in ACE activity in
serum, it is not related to the activity of ACE within the dermal tissues. I conclude that the
skin responses to bradykinin as determined by wheal area are not related to ACE genotype and
there is therefore no evidence for a relationship between the polymorphism in the ACE gene
and membrane-bound ACE activity in this tissue.
In summary:
• The relations between ACE genotype and wheal responses to intradermal bradykinin
and histamine were studied in 105 healthy subjects, 30 of genotype DD, 51 of
genotype ID and 24 of genotype II.
• Bradykinin and histamine produced significant linear log dose - wheal area responses.
• The potency of bradykinin in II subjects relative to DD subjects was 1.25, with the
95% CI (0.71-1.98) indicating no significant difference between the genotypes
• The ACE gene polymorphism does not predict dermal bradykinin responses, which
are a measure of tissue ACE activity.
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Chapter 9
ACE GENOTYPE AND ACE INHIBITOR COUGH
ill
9.1 INTRODUCTION
It remains uncertain why only about 20% of subjects develop a cough when taking ACE
inhibitor treatment. Genetic factors certainly contribute to the susceptibility to develop adverse
reactions to certain drugs and it may be that they are involved with this unusual effect. It has
been hypothesised that the cough may be related to an accumulation of kinins due to reduced
ACE activity (Yeo 1991). If this is the case one might expect the ACE genotype, a strong
predictor of ACE activity, to be related to susceptibility to develop cough. In particular, those
with a low ACE activity such as individuals of genotype II, might have greater accumulation of
kinins and thus be more likely to develop cough.
I aimed to examine this theory by studying the distribution of genotypes amongst subjects who
had developed a new cough when treatment with ACE inhibitors was commenced.
9.2 AIMS
1. To examine the distribution of I and D alleles in subjects with ACE inhibitor cough.
9.3 METHODS
9.3. J Study design and subjects Records of the Sheffield hypertension clinic were examined
and those patients with a cough which was considered to be due to ACE inhibitor drugs (as
defined in chapter 2.5.1.3) were invited to attend for a blood test. A 5ml blood sample was
obtained which was used for DNA testing of the ACE genotype as discussed in chapter 2.
A control group consisting healthy subjects was obtained by open invitation. Ethics approval
was obtained as before.
9.3.2 Statistical analyses
Groups were compared by Chi-square tests.
9.4 RESULTS
31 patients with a cough which could be attributed to ACE inhibitors were identified and
agreed to be genotyped compared with 221 healthy controls. These patients consisted of 25
women and 7 men ofmean age 58.7 years (sd 12.8) taking a mean 2.2 medications (sd 0.7).
There were no significant differences between the distribution of genotypes (Table 9.1).
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Table 9.1 British patients with ACE inhibitor cough (Bl, n=31), Healthy British control
population (B2, n=221) according to ACE genotype.
Group Genotype Allele distribution
I DII ID DD
Those with cough (Bl) 6 12 13 0.39 0.61
Those without cough (B2) 58 97 66 0.48 0.52
9.5 DISCUSSION
In this study I examined the distribution of genotypes for the ACE gene polymorphism in a
group of patients with cough due to ACE inhibitors.
No significant difference in ACE genotype was observed between those with cough and either a
healthy population or a group without cough due to ACE inhibitors. There was no excess of
genotype II in the group who coughed; nor did DD protect against cough. This finding was
confirmed in a French population (Kreft-Jaisl994) who also examined a group of those who
developed cough with ACE inhibitors. The control groups in this study consisted of patients
taking ACE inhibitors and not coughing and a population of hypertensive patients (Table 9.2).
There has been no comincing relationship demonstrated between hypertension and ACE
genotype in Western populations at present (Cambien 1988, Harrap 1993, Schmidt 1993).
Interestingly in a Japanese population an excess of II was indeed found (Furuya 1994; Table
2). This may represent racial differences as not only has the ACE genotype been linked to
hypertension in this racial group (Morise 1994) but a higher incidence of cough has been found
in Chinese, among whom the population prevalence of the I allele is high (Chan 1993, Lee
1994). It has been suggested that the reasons for this difference between European and Asian
populations may reflect differences in haplotype or expression of the gene betw een these
populations of the angiotensin converting enzyme gene (Kreft-Jaisl994). Alternatively, and
probably more likely, the findings may be due to chance particularly as these studies are often
case-control in nature and of undetermined power.
In conclusion in a cohort of patients with hypertension who developed a cough whilst on ACE
inhibitor treatment there was no relationship between ACE genotype distribution or frequency
of tire I allele. The ACE genotype is unlikely to be involved in the pathogenesis of ACE
inhibitor cough in Western populations.
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Table 9.2: ^British patients with ACE inhibitor cough (Bl, n=31), Healthy British control
population (B2, n=221), French patients with ACE inhibitor cough (Fl, n=75), French patients
without cough on enalapril (F2, n=71), Hypertensive French control (F3, n=206), Japanese










Bl 6 12 53 "V0'39 0.61
B2 58 97 66 0.48 0.52
Fl I'd ' 33
.
:'' 30 0.38 0 62
F2 15 29 27 0.42 0.58
F3 42 95 69 0.44 0.56
J1 19 12 .0 081 O.io
J2 25 35 11 0.6 0.4
In summary:






It has taken 100 years to learn what we now know on the renin-angiotensin system. From what
was a slow and uncertain path the rate of understanding has been exponential in recent years.
The recent discovery of a genetic variation in the ACE gene that might affect responses to
either substrates or inhibitors ofACE and also possibly act as a risk factor for cardiovascular
disease (Cambien 1992) has been the focus for studies in this thesis.
I therefore aimed to study the responses of healthy subjects of different genotype for the I/D
ACE gene polymorphism to establish whether the differences that occurred in serum ACE
activity were mirrored by differences in tissue ACE activity. This was done by studying the
vascular responses to angiotensin I and ACE inhibitors in subjects of different ACE genotype.
ACE inhibitor drugs are now commonly prescribed for patients with hypertension and heart
failure with little prospect of the frequency with which they are used diminishing (Mclnnes
1993). With an increase in use of any drug will follow an increase in adverse effects and it is
important that we continue to examine these side effects. It would be hoped that we can learn
not only more about the clinical pharmacology but that eventually through this knowledge
better treatments might be developed. Thus I examined cough, a common side effect of ACE
inhibitors, with particular emphasis on elucidating its effects on the cough reflex and the role of
various peptide mediators in its pathogenesis. Thereafter I examined the hypothesis that
responses to bradykinin might be determined by ACE genotype in healthy subjects. Finally I
examined whether ACE genotype might be related to the development of ACE inhibitor cough.
10.1 Does an individuals ACE genotype determine responses to substrates of
angiotensin converting enzyme?
A strong relationship between ACE genotype and serum ACE has been observed consistently
by others (Rigat 1990, Ueda 1994) and in our own laboratory. Subjects of genotype II have
serum ACE activity that is approximately 50% that of DD subjects (Cambien 1994). At
present it is unclear whether the relation between ACE genotype and serum ACE is paralleled
by a relation of the genotype to tissue ACE, that is the membrane-bound form ACE, the
predominant form in the heart, lungs and vascular endothelium. There is some evidence ACE
genotype and tissue ACE might be related from in-vitro studies (Costerousse 1993), but
studies in humans examining this question indirectly through the responses to substrates of
ACE have only recently been performed. The relation of the ACE genotype to membrane-
bound ACE activity in tissue which unlike serum ACE, is thought to effect the physiological
and pathophysiological actions of ACE (Soubrier 1993), is important because of numerous
reports linking the ACE genotype to various cardiovascular disorders (Cambien 1994, Tirer
1993, Raynolds 1993, Schunkert 1994).
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In this thesis I examined the vascular responses of subjects of different ACE genotype to
angiotensin I and ACE inhibitors. If the relation of genotype to serum ACE was paralleled by a
similar relation to tissue ACE one would anticipate an association between the ACE genotype
and responses of angiotensin I or ACE inhibitor. For example if the higher serum ACE activity
of DD subjects relative to II subjects was mirrored by an increase in tissue ACE activity in DD
subjects, they would be expected to have greater responses to angiotensin I and smaller
responses to ACE inhibitors.
Vascular responses and the ACE genotype
The pressor response to angiotensin I was not found to be related to ACE genotype. This
agrees with the findings of Menard et al (1995) but contrasts with the results of Ueda et al who
reported that subjects of genotype DD did have enhanced pressor responses to angiotensin I
(Ueda et al 1995). All the studies were of similar magnitude and thus there remains doubt as to
the true involvement in ACE genotype in determining pressor responses to Angiotensin I. I
also examined some neurohormonal responses. Perhaps those of different genotype might have
differing amounts of the end product of the renin cascade- angiotensin II. Differing effects on
the downstream production of angiotensin II were not seen in my study or indeed in a large
study where normotensive subjects of different ACE genotype had various parameters from the
RAA system measured (Harrap 1993).
I examined the blood pressure and serum ACE responses to enalapril in healthy subjects to
ascertain if there was any possible role of the ACE genotype. I found that the ACE genotype
influences serum ACE activity under normal conditions and after a single oral dose of
enalapril, and also predicts the acute responses of serum ACE activity to a single dose of
enalapril. However I found no evidence that the ACE genotype predicts the acute
pharmacodynamic response to enalapril in terms of blood pressure responses. Preliminary
results from similar work agrees with my results (O'Kane 1996) My observations relate to a
relatively low single dose of enalapril, and it will be of interest to examine whether higher doses
or chronic treatment abolish serum ACE differences between the genotypes.
It would seem unlikely therefore that the ACE genotype can determine vascular responses
either as pressor response to Angiotensin I or hypotensive responses to ACE inhibitors with
possible reasons for this being discussed below.
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Bradykinin responses and the ACE genotype
When I examined the effect of inhaled bradykinin it produced cough in healthy subjects but this
does not appear to be related to ACE genotype. Unfortunately this study was flawed in design
in that the same order of administration was used for each subject. This design fault probably
exaggerated the tachyphylaxis which seems to be seen with inhaled bradykinin (Polosa 1992a).
However when the first dose response was examined there did not seem to be significant
differences although the small sample size might conceal these.
In the study of dermal responses to bradykinin I adopted a different approach to examine the
relation between the ACE genotype and activity of ACE in tissue. It has been shown that
treatment with ACE inhibitors increases the dermal response to bradykinin, indicating that this
response to bradykinin is a measure of ACE activity at the tissue level (Ferner 1989, Fuller
1987). If the relation of genotype to serum ACE was paralleled by a similar relation to tissue
ACE one would anticipate an association between the ACE genotype and responses of
intradermal injection of bradykinin. For example if the higher serum ACE activity ofDD
subjects relative to II subjects was mirrored by an increase in tissue ACE activity in DD
subjects, they would be expected to have smaller wheal responses to bradykinin. Likewise
dermal responses to histamine which is not metabolised by ACE (Anderson 1990) would be
unrelated to the ACE genotype. My results show no significant difference in the potency of
bradykinin in dermal wheal response between subjects of DD and II genotypes although there
was a trend for subjects of genotype II to have larger responses to bradykinin. The study had
sufficient power to exclude a potency in II subjects greater than 1.88 relative to DD subjects.
Moreover the findings for intradermal histamine, whose effect is independent ofACE, were
similar to those for bradykinin with a trend towards a slightly higher potency in subjects of II
genotype. Thus the polymorphism in the ACE gene which is associated with a marked
difference in ACE activity in serum shows no relation to the activity ofACE in dermal tissues.
These findings do not support a role for the ACE genotype in the physiological action ofACE
at the tissue level.
Unfortunately it is unlikely that individually my studies involving examination of ACE
genotype had sufficient power to exclude with any certainty differences between genotype of a
small magnitude. Most of them excluded differences of a large magnitude how ever. When
taken together my studies lead me to doubt whether there is a role for the ACE genotype in the
physiological action of ACE at the tissue level.
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Why might the ACE genotype have no role to play in determining membrane-bound ACE or
there being phenotypic differences in subjects of differing genotype? There could be several
explanations for this. Firstly the experimental models of tissue ACE that I used may not be
optimal and could include too many other variables. This would be best solved by using
isolated tissue preparations but this is clearly difficult and to my knowledge has only been done
by Costerousse (1993) using T lymphocytes and more recently in cardiac tissue (Jan Danser
1995). Vascular responses in-vivo show great variability and obtaining a suitable sample size
may be problematic. Determining the responses of serum ACE to ACE inhibitors are limited
by measurement ofACE activity in the presence of some ACE inhibitors ie captopril. This will
mean long-acting agents are used with subsequent practical difficulties in recruitment for
volunteer studies unless solely blood pressure response is examined.
Secondly my studies are relatively small and the variability in response quite large. My results
would give others an idea of the variability and allow a more accurate estimation of sample
size. Others have tried to minimise variation using sodium depletion or the use of an intra¬
venous pro-drug (O'Kane 1996, Ueda 1996) however the variation in response remains
considerable.
Finally, there may of course be no role of the ACE I/D polymorphism in determining tissue
ACE responses. At most it is only a marker in linkage disequilibrium with the locus, as yet
unidentified, responsible for regulating serum ACE levels (Lindpainter 1995). The true locus
responsible for determining ACE level is considered to lie within the promoter region of the
ACE gene and if identified then further work would need to be done to re-group subjects
according to genotype. Even then it may be difficult to identify phenotypic differences apart
from ACE level.
Until recently it was not appreciated how even simple gene defects might exhibit phenotypic
complexity. Research into diseases such as cystic fibrosis and Huntingdon's chorea was
considered to be advanced by the discovery of the gene defect. Unfortunately in both these
diseases the genotype does not always predict the phenotype (Alper 1996). This may be due to
reduced penetrance, variable expressivity, variable sets of symptoms (pleiotropy) or the effects
of age on presentation (Alper 1996).
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I would suggest that reports linking the ACE genotype to various cardiovascular and other
(Ruiz 1994) disorders due to possible phenotypic variation in the RAA, often based upon
rather unsatisfactory evidence (Teo 1995), should be viewed with caution until such times as
the ACE genotype has been shown to have an association with some physiological activity.
My view is strengthened by the recent publication of prospective studies that have failed to
confirm a relationship between ACE genotype and cardiovascular disease (Harrap 1993,
Lindpainter 1995, Lindpainter 1996).
10.3 What are the effects ofACE inhibitors on the cough reflex?
10.3.1 The cough due to ACE inhibitors
Cough is now accepted as a common and troublesome effect of treatment with ACE inhibitors.
I examined the effects on the cough reflex of patients starting treatment with ACE inhibitors.
Patients starting enalapril who developed a new onset of persistent cough during a one year
follow-up reported significantly more cough by questionnaire and visual analogue scales at
one month than did controls. The patients had normal sensitivity to inhaled capsaicin initially
but a five fold increase at one month. By contrast in those with no cough and in controls
capsaicin sensitivity was reduced. ACE inhibitor treatment appears to shift the capsaicin dose-
response only in those who develop spontaneous cough, not in all patients treated.
ACE inhibitor cough is thought to resolve rapidly, within one week of stopping treatment
(Coulter 1987, Berkin 1989), but these impressions predate quantitative methods of assessing
ACE inhibitor cough (Yeo 1991, Fletcher 1990, Yeo 1994). I studied the resolution of cough
related to enalapril after the ACE inhibitor was stopped. The cough certainly improved on
cessation of treatment with reductions in measures of the severity and frequency of cough and
night-time cough, but resolution took longer than one week. There was a significant
improvement 14 days after stopping enalapril, but complete loss of the cough was observed
only after 28 days.
There was a highly significant association between cough responses to capsaicin and
measurements of severity and frequency of cough by visual analogue scales. This supports
both the findings of myself and others that the abnormality underlying ACE inhibitor cough is
an increase in C-fibre mediated sensitivity of the cough reflex (Fuller 1987, McEwan 1989,
Yeo 1994). With the exception of severe cough, there was no significant association between
cough measured by questionnaire and capsaicin sensitivity, suggesting that the visual analogue
scales may be more sensitive than the questionnaire for measuring cough. While the significant
increase in capsaicin sensitivity in patients with ACE inhibitor cough is well established (Fuller
1987, Yeo 1994) there is little information on changes in capsaicin sensitivity over time within
patients. My study shows a substantial and highly significant reduction in sensitivity of the
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cough reflex to capsaicin after stopping enalapril. The five-fold fall in potency of capsaicin
over 28 days after stopping enalapril in the study in chapter 6 is identical to the five-fold
difference in relative potency observed between patients with ACE inhibitor cough and control
subjects found in chapter 5, and suggests that the cough reflex had returned to normal four
weeks after stopping treatment.
10.3.2 What is the role ofkinins?
It has been considered for some time that kinins have a role in the pathogenesis of ACE
inhibitor cough (Yokosawa 1985, Thysell 1988, Morice 1987). This has been further
confirmed by recent work where a specific angiotensin II antagonist losartan was compared to
lisinopril in patients with ACE inhibitor cough (Lacourciere 1994). When I studied the
discontinuation of treatment in those with cough I found the wheal area in response to
intradermal bradykinin and substance-P showed progressive and highly significant declines
after stopping enalapril. These findings give some support to the hypothesis (Coulter 1987,
Berkin 1989) that bradykinin may be a mediator of ACE inhibitor cough. Although the dermal
responses to substance-P were associated with ACE inhibitor withdrawal they were not linked
to changes in cough response. However intradermal responses to these peptides may not reflect
events in the respirator}- tract, and there may be type II error as the sample size was small.
Changes in capsaicin sensitivity parallel those in subjective cough supporting suggestions that
ACE inhibitor cough is caused by facilitation of the C-fibre mediated cough reflex. Change in
response to intradermal bradykinin was a better predictor of cough responses than that for
substance-P, and accounted for about a quarter of unexplained variability in the changes in
visual analogue scales for cough during the resolution of ACE inhibitor cough.
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10.4 Is the ACE genotype linked to ACE inhibitor cough?
In subjects with ACE inhibitor cough I examined the distribution ofACE genotype. I found no
evidence that the frequency distribution of alleles was any different in those who cough
compared to healthy controls. Subsequently this has been confirmed by others examining other
European populations (Kreft-Jais 1994) but interestingly data from Far Asian population
showed an increase in those ofgenotype II (Furuya 1994). These geographical variations I feel
have more to do with sampling differences than actual genetic reasons. It is unlikely that the
ACE genotype has any role in determining who develops cough due ACE inhibitors.
Conclusions of thesis
In summary, this thesis has explored various aspects of the renin-angiotensin system with
particular emphasis on ACE inhibitor cough and the ACE genotype. I have established that
when a cough develops in a patient on ACE inhibitor treatment this is likely to have been
accompanied by a change in the cough reflex probably mediated by kinins. I have also
established that in healthy subjects their responses to both substrates ofACE (angiotensin I and
bradykinin) and ACE inhibitors are not likely to be related to ACE genotype.
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Appendix 1.
An example of the self-administered questionnaire used in the studies on cough, chapters 5
and 6 (Fletcher 1990, Yeo 1991, Lacourciere 1994).
SHEFFIELD HYPERTENSION CLINIC SURVEY ON DRUG SIDE EFFECTS
PLEASE ANSWER THE FOLLOWING OUESTIONS:-
DO YOU SUFFER FROM ANY OF THE FOLLOWING?
YES NO
Asthma [ ] [ ]
Chronic Bronchitis [ ] [ ]
Emphysema [ ] [ ]
Do you have any of the complaints listed below? Please complete for each question.
















DO YOU GET HEADACHES REGULARLY?
YES[ ] NO[ ]
HOW OFTEN DO YOU GET THEM?
WHEN DID THEY START?






































Other people complain Have you consulted
about you always your GP about the
having a headache? headache?
YES [ ] YES [ ]
NO [ ] NO [ ]
DO YOU HAVE A PERSISTENT COUGH? YES [ ] NO [ ]
HOW OFTEN DO YOU GET IT?
WHEN DID IT START?
TICK ONE OF THE BOXES IN EACH SQUARE WHICH BEST DESCRIBES YOUR
COUGH
Dry cough [ ] Daytime [ J
Intermittent ]
Produces phlegm [ ] Night-time [ ]
Continuous [ ]
Blood with phlegm [ ] Day & night [ ]
cough[]
Other [ ] Give details
Severe [ ] Vomiting with Sleep disturbed
cough by cough
Moderate [ ] YES [ ] YES [ ]
NO [ ] NO [ ]
Mild [ ]
Other people complain Have you consulted
about your cough? your GP about the cough?
YES [ ] YES [ ]
NO [ ] NO [ ]
DO YOU SMOKE ? YES [ ] NO [ ]
IF YES:- Cigarettes [ ] Pipe [ ] Cigars [ ]
Bouts of
IF CIGARETTES:
How many cigarettes per day ?
(please insert number in box) [ ] cigarettes per day.
HOW OLD WERE YOU WHEN YOU STARTED SMOKING ?
ARE YOU AN EX-SMOKER? YES [ ] NO [ ]
IF YES,AT WHAT AGE DID YOU STOP?[ ] yrs
HOW MANY DID YOU SMOKE EACH DAY?[ ] cigarettes
PLEASE LIST YOUR TABLET TREATMENT BELOW
(Remember to include inhalers, oral suspensions and suppositories, etc)
(You willfind the name ofthe tablet, strength and dose on the
bottle or packet from your chemist)
[ ]yrs
Appendix 2
An example of the diary used to collect information on cough following ceassation of the ACE
inhibitor.
SYMPTOMS ASSESSMENT-COUGH REPORT FORM
PATIENTS NAME DATE
INSTRUCTIONS TO PATIENT : COMPLETION OF THE CARD
In the morning ,please indicate the severity of any nightime cough. In the evening indicate the
severity of any symptoms throughout the day.
SCORING OF SYMPTOMS
On this page there is a list ofwords that determine symptoms people have. Please read each
one carefully, then enter one number to represent the extent to which the symptom has
bothered you. Be sure to mark one box for each day.
Not at all A little Moderately Quite a bit Extremely
0 1 2 3 4


















Read the statements at each end of the line carefully, then mark the line, to describe how
you have been, in the way shown below.
I am never thirsty I am always thirsty
I never cough I am always coughing
Cough has been absolutely
no trouble to me
My cough has been as
bad as it could possibly
be
I never have headache I always have headache
Headache have been
absolutely no trouble to me
My headaches have
been as bad as they
could possibly be
